H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 1
PA Criteria
Prior Authorization Group ABIRATERONE
Drug Names ABIRATERONE ACETATE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Node-positive (N1), non-metastatic (M0) prostate cancer
Exclusion Criteria -
Required Medical Information The requested drug will be used in combination with a gonadotropin-releasing hormone
(GnRH) analog or after bilateral orchiectomy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ACITRETIN
Drug Names ACITRETIN
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Prevention of non-melanoma skin cancers in high risk individuals, Lichen planus,
Keratosis follicularis (Darier Disease)
Exclusion Criteria -
Required Medical Information Psoriasis: The patient has experienced an inadequate treatment response, intolerance,
or the patient has a contraindication to methotrexate or cyclosporine.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ACTIMMUNE
Drug Names ACTIMMUNE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Mycosis fungoides, Sezary syndrome.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 2
Prior Authorization Group ADEMPAS
Drug Names ADEMPAS
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group
1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1)
pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2)
pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg,
AND pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood
units.
3)
For chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4):
1) Patient has persistent or recurrent CTEPH after pulmonary endarterectomy (PEA),
OR Patient has inoperable CTEPH with the diagnosis confirmed by right heart
catheterization AND by computed tomography (CT), magnetic resonance imaging
(MRI), or pulmonary angiography.
2)
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group AIMOVIG
Drug Names AIMOVIG
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The patient received at least 3 months of treatment with the requested drug, and the
patient had a reduction in migraine days per month from baseline, OR The patient
2)
experienced an inadequate treatment response with a 4-week trial of any of the
following: Antiepileptic drugs (AEDs), Beta-adrenergic blocking agents,
Antidepressants, OR The patient experienced an intolerance or has a
3)
contraindication that would prohibit a 4-week trial of any of the following: Antiepileptic
drugs (AEDs), Beta-adrenergic blocking agents, Antidepressants.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Initial 3 months, Reauthorization Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 3
Prior Authorization Group ALDURAZYME
Drug Names ALDURAZYME
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For mucopolysaccharidosis I: Diagnosis of mucopolysaccharidosis I was confirmed by
an enzyme assay demonstrating a deficiency of alpha-L-iduronidase enzyme activity or
by genetic testing. Patients with Scheie syndrome must have moderate to severe
symptoms.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ALECENSA
Drug Names ALECENSA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent ALK-positive non-small cell lung cancer (NSCLC), brain metastases from
ALK-positive NSCLC.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ALOSETRON
Drug Names ALOSETRON HYDROCHLORIDE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The requested drug is being prescribed for a biological female or a person that self-
identifies as a female with a diagnosis of severe diarrhea-predominant irritable bowel
syndrome (IBS) AND Chronic IBS symptoms lasting at least 6
2) months AND 3)
Gastrointestinal tract abnormalities have been ruled out AND 4) Inadequate response
to one conventional therapy (e.g., antispasmodics, antidepressants, antidiarrheals).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 4
Prior Authorization Group ALPHA1-PROTEINASE INHIBITOR
Drug Names ARALAST NP, PROLASTIN-C, ZEMAIRA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For alpha1-proteinase inhibitor deficiency: Patient must have clinically evident
1)
emphysema and pretreatment serum alpha1
2) -proteinase inhibitor level less than 11
micromol/L (80 mg/dL by radial immunodiffusion or 50 mg/dL by nephelometry).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ALUNBRIG
Drug Names ALUNBRIG
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent ALK-positive non-small cell lung cancer (NSCLC), brain metastases from
ALK-positive NSCLC.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group AMBRISENTAN
Drug Names AMBRISENTAN
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information Pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1):
Diagnosis was confirmed by right heart catheterization. For PAH new starts only: 1)
Pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, 2)
Pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg,
and Pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood
3)
units.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 5
Prior Authorization Group AMPHETAMINES
Drug Names AMPHETAMINE/DEXTROAMPHETA
PA Indication Indicator All Medically-accepted Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or
Attention Deficit Disorder (ADD) OR The patient has a diagnosis of narcolepsy
2)
confirmed by a sleep study.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ARCALYST
Drug Names ARCALYST
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Prevention of gout flares in patients initiating or continuing urate-lowering therapy.
Exclusion Criteria -
Required Medical Information For prevention of gout flares in patients initiating or continuing urate-lowering therapy
(e.g., allopurinol) (new starts): two or more gout flares within the previous 12 months,
1)
AND inadequate response, intolerance or contraindication to
2) maximum tolerated
doses of a non-steroidal anti-inflammatory drug (NSAID) and colchicine, AND 3)
concurrent use with urate-lowering therapy. For prevention of gout flares in patients
initiating or continuing urate-lowering therapy (e.g., allopurinol) (continuation): patient
1)
must have achieved or maintained a clinical benefit (i.e., a fewer number of gout
attacks or fewer flare days) compared to baseline, AND continued use of urate
2) -
lowering therapy concurrently with the requested drug.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration For prevention of gout flares: 4 months. Other: Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 6
Prior Authorization Group ARMODAFINIL
Drug Names ARMODAFINIL
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The patient has a diagnosis of narcolepsy and the diagnosis is confirmed by sleep
lab evaluation OR The patient has a diagnosis of Shift Work Disorder (SWD) OR 3)
2)
The patient has a diagnosis of obstructive sleep apnea (OSA) and the diagnosis is
confirmed by polysomnography.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group AUSTEDO
Drug Names AUSTEDO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Tourette's syndrome
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 7
Prior Authorization Group AVASTIN
Drug Names AVASTIN
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Breast cancer, central nervous system (CNS) tumor types: adult low-grade (WHO
Grade II) infiltrative supratentorial astrocytoma/oligodendroglioma, adult intracranial
and spinal ependymoma, anaplastic gliomas, adult medulloblastoma, primary central
nervous system lymphoma, meningiomas, limited and extensive brain metastases,
metastatic spine tumors, malignant pleural mesothelioma, ovarian cancer/fallopian tube
cancer/primary peritoneal cancer types: carcinosarcoma (malignant mixed Mullerian
tumors), clear cell carcinoma, mucinous carcinoma, grade 1 endometrioid carcinoma,
low-grade serous carcinoma, ovarian borderline epithelial tumors (low malignant
potential) with invasive implants, and malignant sex cord-stromal tumors, soft tissue
sarcoma types: angiosarcoma and solitary fibrous tumor/hemangiopericytoma, uterine
neoplasms, endometrial carcinoma, vulvar squamous cell carcinoma, and ophthalmic-
related disorders: diabetic macular edema, neovascular (wet) age-related macular
degeneration including polypoidal choroidopathy and retinal angiomatous proliferation
subtypes, macular edema following retinal vein occlusion, proliferative diabetic
retinopathy, choroidal neovascularization, neovascular glaucoma and retinopathy of
prematurity, small bowel adenocarcinoma.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual. The
patient had an intolerable adverse event to both Mvasi AND Zirabev and that adverse
event was NOT attributed to the active ingredient as described in the prescribing
information.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 8
Prior Authorization Group AYVAKIT
Drug Names AYVAKIT
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Myeloid and lymphoid neoplasms with eosinophilia, gastrointestinal stromal tumor
(GIST) for unresectable, recurrent, or metastatic disease without platelet-derived
growth factor receptor alpha (PDGFRA) exon 18 mutation
Exclusion Criteria -
Required Medical Information For myeloid and lymphoid neoplasms with eosinophilia, the patient meets all of the
following criteria: the disease is FIP1L1
1) - PDGFRA rearrangement-positive, AND 2)
The disease harbors a PDGFRA D842A mutation, AND The disease is resistant to
3)
imatinib. For GIST, the patient meets either of the following criteria: The disease
1)
harbors PDGFRA exon 18 mutation, including PDGFRA D842V mutations, OR The
2)
requested drug will be used after failure on at least two FDA-approved therapies in
unresectable, recurrent, or metastatic disease without PDGFRA exon 18 mutation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 9
Prior Authorization Group B VS. D
Drug Names ABELCET, ABRAXANE, ACETYLCYSTEINE, ACYCLOVIR SODIUM, ADRIAMYCIN,
ALBUTEROL SULFATE, ALIMTA, AMBISOME, AMINOSYN-PF 7%, AMPHOTERICIN
B, APREPITANT, AZACITIDINE, AZATHIOPRINE, BENDEKA, BUDESONIDE,
CALCITONIN-SALMON, CALCITRIOL, CARBOPLATIN, CINACALCET
HYDROCHLORIDE, CISPLATIN, CLINIMIX 4.25%/DEXTROSE 1, CLINIMIX
4.25%/DEXTROSE 5, CLINIMIX 5%/DEXTROSE 15%, CLINIMIX 5%/DEXTROSE
20%, CLINIMIX 6/5, CLINIMIX 8/10, CLINIMIX 8/14, CLINISOL SF 15%, CLINOLIPID,
CROMOLYN SODIUM, CYCLOPHOSPHAMIDE, CYCLOSPORINE, CYCLOSPORINE
MODIFIED, CYTARABINE AQUEOUS, DEXTROSE 50%, DEXTROSE 70%,
DIPHTHERIA/TETANUS TOXOID, DOCETAXEL, DOXORUBICIN HCL,
DOXORUBICIN HYDROCHLORIDE, DRONABINOL, ENGERIX-B, EPIRUBICIN HCL,
ETOPOSIDE, EVEROLIMUS, FLUOROURACIL, FREAMINE HBC 6.9%, FREAMINE
III, FULVESTRANT, GAMASTAN, GANCICLOVIR, GEMCITABINE HCL,
GEMCITABINE HYDROCHLORIDE, GENGRAF, GRANISETRON HCL, HEPARIN
SODIUM, HEPATAMINE, HUMULIN R U-500 (CONCENTR, IBANDRONATE
SODIUM, IMOVAX RABIES (H.D.C.V.), INTRALIPID, INTRON A, IPRATROPIUM
BROMIDE, IPRATROPIUM BROMIDE/ALBUT, IRINOTECAN, IRINOTECAN
HYDROCHLORIDE, KADCYLA, LEUCOVORIN CALCIUM, LEVALBUTEROL,
LEVALBUTEROL HCL, LEVOCARNITINE, LIDOCAINE HCL, LIDOCAINE
HYDROCHLORIDE, METHOTREXATE, METHOTREXATE SODIUM,
METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETAT,
METHYLPREDNISOLONE SODIUM, MORPHINE SULFATE, MYCOPHENOLATE
MOFETIL, MYCOPHENOLIC ACID DR, NULOJIX, NUTRILIPID, ONDANSETRON
HCL, ONDANSETRON HYDROCHLORIDE, ONDANSETRON ODT, OXALIPLATIN,
PACLITAXEL, PAMIDRONATE DISODIUM, PARAPLATIN, PARICALCITOL,
PENTAMIDINE ISETHIONATE, PLENAMINE, PREDNISOLONE, PREDNISOLONE
SODIUM PHOSP, PREDNISONE, PREDNISONE INTENSOL, PREMASOL,
PROCALAMINE, PROGRAF, PROSOL, RABAVERT, RECOMBIVAX HB,
SANDIMMUNE, SIROLIMUS, TACROLIMUS, TDVAX, TENIVAC, TOPOSAR, TPN
ELECTROLYTES, TRAVASOL, TROPHAMINE, VINCRISTINE SULFATE,
VINORELBINE TARTRATE, XATMEP, ZOLEDRONIC ACID, ZORTRESS
PA Indication Indicator All Medically-accepted Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration N/A
Other Criteria This drug may be covered under Medicare Part B or D depending upon the
circumstances. Information may need to be submitted describing the use and setting of
the drug to make the determination.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 10
Prior Authorization Group BALVERSA
Drug Names BALVERSA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group BANZEL
Drug Names RUFINAMIDE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions 1 year of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group BENLYSTA
Drug Names BENLYSTA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria For patients new to therapy: severe active central nervous system lupus.
Required Medical Information For systemic lupus erythematosus (SLE): Patient is currently receiving a stable
1)
standard therapy regimen (e.g., corticosteroid or antimalarial) for SLE OR patient is
2)
not currently receiving stable standard therapy regimen for SLE because patient tried
and had an inadequate response or intolerance to stable standard therapy regimen.
For lupus nephritis: 1) Patient is currently receiving a stable standard therapy regimen
(e.g., corticosteroid) for lupus nephritis OR patient is not currently receiving a stable
2)
standard therapy regimen for lupus nephritis because patient tried and had an
inadequate response or intolerance to a stable standard therapy regimen.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 11
Prior Authorization Group BERINERT
Drug Names BERINERT
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For hereditary angioedema (HAE): The requested drug is being used for the treatment
of acute angioedema attacks. Patient has HAE with C1 inhibitor deficiency or
dysfunction confirmed by laboratory testing OR patient has HAE with normal C1
inhibitor confirmed by laboratory testing. For patients with HAE with normal C1 inhibitor,
EITHER 1) Patient tested positive for an F12, angiopoietin-1, plasminogen, or
kininogen-1 (KNG1) gene mutation OR 2) Patient has a family history of angioedema
and the angioedema was refractory to a trial of an antihistamine for at least one month.
Age Restrictions -
Prescriber Restrictions Immunologist, allergist, rheumatologist
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group BETASERON
Drug Names BETASERON
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group BEXAROTENE
Drug Names BEXAROTENE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Mycosis fungoides, Sezary syndrome, CD30-positive primary cutaneous anaplastic
large cell lymphoma, CD30-positive lymphomatoid papulosis.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 12
Prior Authorization Group BOSENTAN
Drug Names BOSENTAN
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group
1): Diagnosis was confirmed by right heart catheterization. For PAH new starts only: 1)
Pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, 2)
Pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg,
and 3) Pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood
units.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group BOSULIF
Drug Names BOSULIF
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
Exclusion Criteria -
Required Medical Information For chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL): Diagnosis
was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene. For
CML, including patients newly diagnosed with CML and patients who have received a
hematopoietic stem cell transplant: patient has experienced resistance or intolerance to
imatinib or dasatinib. If patient experienced resistance to an alternative tyrosine kinase
inhibitor for CML, patient is negative for all of the following mutations: T315I, G250E,
V299L, and F317L.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 13
Prior Authorization Group BRAFTOVI
Drug Names BRAFTOVI
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Adjuvant systemic therapy for cutaneous melanoma
Exclusion Criteria -
Required Medical Information For colorectal cancer: The patient must meet both of the following criteria: 1) Tumor is
positive for BRAF V600E mutation, 2) The requested drug will be used for either of the
following: a) as subsequent therapy for advanced or metastatic disease, or b) as
primary treatment for unresectable metachronous metastases. For cutaneous
melanoma: The patient must meet all of the following criteria: 1) Tumor is positive for
BRAF V600 activating mutation (e.g., V600E or V600K), 2) The requested drug will be
used in combination with binimetinib, and 3) The requested drug will be used for either
of the following: a) unresectable or metastatic disease, or b) adjuvant systemic therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group BRIVIACT
Drug Names BRIVIACT
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The patient has experienced an inadequate treatment response, intolerance, or
contraindication to a generic anticonvulsant AND 2) The patient has experienced an
inadequate treatment response, intolerance, or contraindication to any of the following:
Aptiom, Vimpat, Xcopri, Spritam.
Age Restrictions 1 month of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 14
Prior Authorization Group BRIVIACT INJ
Drug Names BRIVIACT
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The patient has experienced an inadequate treatment response, intolerance, or
contraindication to a generic anticonvulsant AND 2) The patient has experienced an
inadequate treatment response, intolerance, or contraindication to any of the following:
Aptiom, Vimpat, Xcopri, Spritam.
Age Restrictions 16 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group BRUKINSA
Drug Names BRUKINSA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group BUDESONIDE CAP
Drug Names BUDESONIDE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Treatment and maintenance of microscopic colitis in adults
Exclusion Criteria -
Required Medical Information Patient has had a clinical relapse after cessation of treatment (induction) therapy for
use in maintenance of microscopic colitis.
Age Restrictions Crohn's, treatment: 8 years of age or older
Prescriber Restrictions -
Coverage Duration Microscopic colitis, maintenance: 12 months, all other indications: 3 months
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 15
Prior Authorization Group BUPRENORPHINE
Drug Names BUPRENORPHINE HCL
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The requested drug is being prescribed for the treatment of opioid use disorder AND
patient meets one of the following: 1) The patient is pregnant or breastfeeding, and the
requested drug is being prescribed for induction therapy and/or subsequent
maintenance therapy for treatment of opioid use disorder OR 2) The requested drug is
being prescribed for induction therapy for transition from opioid use to treatment of
opioid use disorder OR 3) The requested drug is being prescribed for maintenance
therapy for treatment of opioid use disorder in a patient who is intolerant to naloxone.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 12 months
Other Criteria -
Prior Authorization Group BUPRENORPHINE PATCH
Drug Names BUPRENORPHINE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The requested drug is being prescribed for pain associated with cancer, sickle cell
disease, a terminal condition, or pain being managed through palliative care OR 2) The
requested drug is being prescribed for pain severe enough to require daily, around-the-
clock, long-term treatment in a patient who has been taking an opioid AND 3) The
patient can safely take the requested dose based on their history of opioid use [Note:
This drug should be prescribed only by healthcare professionals who are
knowledgeable in the use of potent opioids for the management of chronic pain.] AND
4) The patient has been evaluated and the patient will be monitored for the
development of opioid use disorder AND 5) This request is for continuation of therapy
for a patient who has been receiving an extended-release opioid agent for at least 30
days OR the patient has taken an immediate-release opioid for at least one week.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 16
Prior Authorization Group CABOMETYX
Drug Names CABOMETYX
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Non-small cell lung cancer
Exclusion Criteria -
Required Medical Information For renal cell carcinoma: The disease is advanced, relapsed, or stage IV. For non-
small cell lung cancer: 1) The disease is rearranged during transfection (RET) positive
AND 2) the disease is recurrent, advanced, or metastatic. For hepatocellular
carcinoma: the requested drug will be used as subsequent treatment.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group CALCIPOTRIENE
Drug Names CALCIPOTRIENE, CALCITRENE, ENSTILAR
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The requested drug is being prescribed for the treatment of psoriasis AND 2) The
patient experienced an inadequate treatment response, intolerance, or the patient has
a contraindication to a topical steroid.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group CALQUENCE
Drug Names CALQUENCE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma
Exclusion Criteria -
Required Medical Information For chronic lymphocytic leukemia or small lymphocytic lymphoma: the patient has
experienced an intolerable adverse event with ibrutinib.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 17
Prior Authorization Group CAPLYTA
Drug Names CAPLYTA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The patient experienced an inadequate treatment response, intolerance, or
contraindication to one of the following generic products: A) aripiprazole, B) asenapine,
C) olanzapine, D) quetiapine, E) risperidone, F) ziprasidone AND the patient
experienced an inadequate treatment response, intolerance, or contraindication to one
of the following brand products: A) Latuda, B) Rexulti, C) Secuado.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group CAPRELSA
Drug Names CAPRELSA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Differentiated thyroid carcinoma: papillary, follicular, and Hurthle cell.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group CARBAGLU
Drug Names CARBAGLU
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For N-acetylglutamate synthase (NAGS) deficiency: Diagnosis of NAGS deficiency was
confirmed by enzymatic or genetic testing.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 18
Prior Authorization Group CAYSTON
Drug Names CAYSTON
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For treatment of respiratory symptoms in cystic fibrosis patients: 1) Pseudomonas
aeruginosa is present in the patient's airway cultures OR 2) The patient has a history of
pseudomonas aeruginosa infection or colonization in the airways.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group CERDELGA
Drug Names CERDELGA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For Gaucher disease, the diagnosis was confirmed by an enzyme assay demonstrating
a deficiency of beta-glucocerebrosidase enzyme activity or by genetic testing. The
patient's CYP2D6 metabolizer status has been established using an FDA-cleared test.
The patient is a CYP2D6 extensive metabolizer, an intermediate metabolizer, or a poor
metabolizer.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group CEREZYME
Drug Names CEREZYME
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Type 2 Gaucher disease, Type 3 Gaucher disease
Exclusion Criteria -
Required Medical Information For Gaucher disease, the diagnosis was confirmed by an enzyme assay demonstrating
a deficiency of beta-glucocerebrosidase enzyme activity or by genetic testing.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 19
Prior Authorization Group CHANTIX
Drug Names CHANTIX, CHANTIX CONTINUING MONTH, CHANTIX STARTING MONTH PA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 6 months
Other Criteria -
Prior Authorization Group CLOBAZAM
Drug Names CLOBAZAM
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions 2 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group CLOMIPRAMINE
Drug Names CLOMIPRAMINE HCL
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Depression, Panic Disorder
Exclusion Criteria -
Required Medical Information 1) The requested drug is being prescribed for one of the following: Obsessive-
Compulsive Disorder (OCD) or Panic Disorder AND 2) The patient has experienced an
inadequate treatment response, intolerance, or the patient has a contraindication to any
of the following: a serotonin and norepinephrine reuptake inhibitor (SNRI) or a selective
serotonin reuptake inhibitor (SSRI) OR 3) The requested drug is being prescribed for
Depression AND 4) The patient has experienced an inadequate treatment response,
intolerance, or the patient has a contraindication to two of the following: serotonin and
norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors
(SSRIs), mirtazapine, bupropion.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 20
Prior Authorization Group CLORAZEPATE
Drug Names CLORAZEPATE DIPOTASSIUM
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For all indications: the prescriber must acknowledge the benefit of therapy with the
requested drug outweighs the potential risks for the patient. (Note: The American
Geriatrics Society identifies the use of this medication as potentially inappropriate in
older adults, meaning it is best avoided, prescribed at reduced dosage, or used with
caution or carefully monitored.) For the management of anxiety disorders: 1) the
requested drug is being used concurrently with a selective serotonin reuptake inhibitor
(SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) until the SSRI/SNRI
becomes effective for the symptoms of anxiety OR 2) the patient has experienced an
inadequate treatment response, intolerance, or has a contraindication to AT LEAST
TWO agents from the following classes: a) selective serotonin reuptake inhibitors
(SSRIs) OR b) serotonin-norepinephrine reuptake inhibitors (SNRIs).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Short-term relief anxiety-1 month, Anxiety Disorders-4 months, All other Diagnoses-
Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 65 years of age or older.
Prior Authorization Group CLOZAPINE ODT
Drug Names CLOZAPINE ODT
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 21
Prior Authorization Group COMETRIQ
Drug Names COMETRIQ
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Non-small cell lung cancer (NSCLC), differentiated thyroid carcinoma: papillary,
follicular, and Hurthle cell.
Exclusion Criteria -
Required Medical Information For NSCLC: The requested medication is used for NSCLC when the patient's disease
expresses rearranged during transfection (RET) gene rearrangements.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group COPIKTRA
Drug Names COPIKTRA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Gastric MALT lymphoma, non-gastric MALT lymphoma, nodal marginal zone
lymphoma, splenic marginal zone lymphoma
Exclusion Criteria -
Required Medical Information For follicular lymphoma, gastric MALT lymphoma, non-gastric MALT lymphoma, nodal
marginal zone lymphoma, and splenic marginal zone lymphoma: the requested drug
will be used as subsequent therapy after at least 2 prior therapies.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 22
Prior Authorization Group COTELLIC
Drug Names COTELLIC
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Central nervous system (CNS) cancer (i.e., glioma, meningioma, astrocytoma)
Exclusion Criteria -
Required Medical Information For adjuvant treatment of melanoma, and central nervous system (CNS) cancer (i.e.,
glioma, meningioma, astrocytoma): The patient must meet both of the following criteria:
1) The tumor is positive for BRAF V600 activating mutation (e.g., V600E or V600K),
and 2) The requested drug will be used in combination with vemurafenib. For
unresectable or metastatic melanoma: The patient must meet both of the following
criteria: 1) The tumor is positive for BRAF V600 activating mutation (e.g., V600E or
V600K), and 2) The requested drug will be used in combination with vemurafenib (with
or without atezolizumab).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group CYSTADROPS
Drug Names CYSTADROPS
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For cystinosis: 1) Diagnosis of cystinosis was confirmed by the presence of increased
cystine concentration in leukocytes or by genetic testing, and 2) Patient has corneal
cystine crystal accumulation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group CYSTAGON
Drug Names CYSTAGON
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For nephropathic cystinosis: Diagnosis of nephropathic cystinosis was confirmed by the
presence of increased cystine concentration in leukocytes or by genetic testing.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 23
Prior Authorization Group CYSTARAN
Drug Names CYSTARAN
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For cystinosis: 1) Diagnosis of cystinosis was confirmed by the presence of increased
cystine concentration in leukocytes or by genetic testing, and 2) Patient has corneal
cystine crystal accumulation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group DALFAMPRIDINE
Drug Names DALFAMPRIDINE ER
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For multiple sclerosis, patient must meet the following: For new starts, prior to initiating
therapy, patient meets the following: patient demonstrates sustained walking
impairment. For continuation of therapy, patient meets the following: patient must have
experienced an improvement in walking speed OR other objective measure of walking
ability since starting the requested drug.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 24
Prior Authorization Group DAURISMO
Drug Names DAURISMO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Post induction therapy following response to previous therapy with the same regimen
for acute myeloid leukemia (AML). Relapsed/refractory AML as a component of
repeating the initial successful induction regimen.
Exclusion Criteria -
Required Medical Information For acute myeloid leukemia: 1) the requested medication must be used in combination
with cytarabine, 2) the patient is 75 years of age or older OR has comorbidities that
preclude intensive chemotherapy, and 3) the requested medication will be used as
treatment for induction therapy, post-induction therapy, or relapsed or refractory
disease.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group DEFERASIROX
Drug Names DEFERASIROX
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For chronic iron overload due to blood transfusions: pretreatment serum ferritin level is
greater than 1000 mcg/L.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group DEMSER
Drug Names METYROSINE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 25
Prior Authorization Group DESVENLAFAXINE
Drug Names DESVENLAFAXINE ER
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information Patient has experienced an inadequate treatment response, intolerance, or the patient
has a contraindication to TWO of the following: serotonin and norepinephrine reuptake
inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), mirtazapine,
bupropion.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group DEXMETHYLPHENIDATE
Drug Names DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HYDROC
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Cancer-related fatigue
Exclusion Criteria -
Required Medical Information 1) The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or
Attention Deficit Disorder (ADD) OR 2) The requested drug is being prescribed for the
treatment of cancer-related fatigue after other causes of fatigue have been ruled out.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group DHE NASAL
Drug Names DIHYDROERGOTAMINE MESYLAT
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The patient has experienced an inadequate treatment response to one triptan 5-HT1
receptor agonist OR 2) The patient has experienced an intolerance to one triptan 5-
HT1 receptor agonist OR 3) The patient has a contraindication that would prohibit a trial
of triptan 5-HT1 receptor agonists.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 26
Prior Authorization Group DIACOMIT
Drug Names DIACOMIT
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group DIAZEPAM
Drug Names DIAZEPAM
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For all indications: the prescriber must acknowledge the benefit of therapy with the
requested drug outweighs the potential risks for the patient. (Note: The American
Geriatrics Society identifies the use of this medication as potentially inappropriate in
older adults, meaning it is best avoided, prescribed at reduced dosage, or used with
caution or carefully monitored.) For the management of anxiety disorders: 1) the
requested drug is being used concurrently with a selective serotonin reuptake inhibitor
(SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) until the SSRI/SNRI
becomes effective for the symptoms of anxiety, OR 2) The patient has experienced an
inadequate treatment response, intolerance, or has a contraindication to AT LEAST
TWO agents from the following classes: a) selective serotonin reuptake inhibitors
(SSRIs), b) serotonin-norepinephrine reuptake inhibitors (SNRIs).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Short-term relief anx-1 mo, skeletal muscle spasm-3 mo, Anx Disorders-4 mo, Other
Diagnoses-PlanYR
Other Criteria This Prior Authorization requirement only applies to patients 65 years of age or older.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 27
Prior Authorization Group DICLOFENAC GEL 1%
Drug Names DICLOFENAC SODIUM
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The patient has osteoarthritis pain in joints susceptible to topical treatment such as
feet, ankles, knees, hands, wrists, or elbows.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group DOPTELET
Drug Names DOPTELET
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For thrombocytopenia associated with chronic liver disease: Baseline platelet count
prior to a scheduled procedure is less than 50,000/mcL. For chronic immune
thrombocytopenia (ITP): 1) For new starts: a) Patient has had an inadequate response
or is intolerant to a prior therapy such as corticosteroids or immunoglobulins, AND b)
Untransfused platelet count at any point prior to the initiation of the requested
medication is less than 30,000/mcL OR 30,000 to 50,000/mcL with symptomatic
bleeding or risk factor(s) for bleeding (e.g., undergoing a medical or dental procedure
where blood loss is anticipated, comorbidities such as peptic ulcer disease and
hypertension, anticoagulation therapy, profession or lifestyle that predisposes patient to
trauma). 2) For continuation of therapy, platelet count response to the requested drug:
a) Current platelet count is less than or equal to 200,000/mcL OR b) Current platelet
count is greater than 200,000/mcL and less than or equal to 400,000/mcL and dosing
will be adjusted to a platelet count sufficient to avoid clinically important bleeding.
Age Restrictions 18 years of age or older
Prescriber Restrictions -
Coverage Duration Chronic liver disease: 1 month, ITP initial: 6 months, ITP reauthorization: Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 28
Prior Authorization Group DRIZALMA
Drug Names DRIZALMA SPRINKLE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Cancer pain, chemotherapy-induced neuropathic pain
Exclusion Criteria -
Required Medical Information 1) The patient has tried duloxetine capsules OR 2) The patient is unable to take
duloxetine capsules for any reason (e.g., difficulty swallowing capsules, requires
nasogastric administration).
Age Restrictions Generalized Anxiety Disorder - 7 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group EMSAM
Drug Names EMSAM
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) Patient has experienced an inadequate treatment response, intolerance, or the
patient has a contraindication to TWO of the following: serotonin and norepinephrine
reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs),
mirtazapine, bupropion OR 2) Patient is unable to swallow oral formulations.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 29
Prior Authorization Group ENBREL
Drug Names ENBREL, ENBREL MINI, ENBREL SURECLICK
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Hidradenitis suppurativa
Exclusion Criteria -
Required Medical Information For moderately to severely active rheumatoid arthritis (new starts only): 1) Inadequate
response, intolerance or contraindication to methotrexate (MTX) OR 2) Inadequate
response or intolerance to a prior biologic disease-modifying antirheumatic drug
(DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis (new starts
only): 1) Inadequate response to a non-steroidal anti-inflammatory drug (NSAID) trial,
OR 2) Intolerance or contraindication to NSAIDs. For moderate to severe plaque
psoriasis (new starts only): 1) At least 3% of body surface area (BSA) is affected OR
crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are
affected at the time of diagnosis, AND 2) Patient meets any of the following: a) Patient
has experienced an inadequate response or intolerance to either phototherapy (e.g.,
UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin,
OR b) Pharmacologic treatment with methotrexate, cyclosporine, or acitretin is
contraindicated, OR c) Patient has severe psoriasis that warrants a biologic DMARD as
first-line therapy (i.e. at least 10% of the BSA or crucial body areas (e.g., hands, feet,
face, neck, scalp, genitals/groin, intertriginous areas) are affected). For hidradenitis
suppurativa (new starts only): patient has severe, refractory disease.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ENDARI
Drug Names ENDARI
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions 5 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 30
Prior Authorization Group EPCLUSA
Drug Names EPCLUSA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For hepatitis C virus (HCV): Infection confirmed by presence of HCV RNA in the serum
prior to starting treatment. Planned treatment regimen, genotype, prior treatment
history, presence or absence of cirrhosis (compensated or decompensated [Child
Turcotte Pugh class B or C]), presence or absence of human immunodeficiency virus
(HIV) coinfection, presence or absence of resistance-associated substitutions where
applicable, liver and kidney transplantation status if applicable. Coverage conditions
and specific durations of approval will be based on current AASLD treatment
guidelines.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Criteria will be applied consistent with current AASLD-IDSA guidance.
Other Criteria -
Prior Authorization Group EPIDIOLEX
Drug Names EPIDIOLEX
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ERGOTAMINE
Drug Names ERGOTAMINE TARTRATE/CAFFE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 31
Prior Authorization Group ERIVEDGE
Drug Names ERIVEDGE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Adult medulloblastoma
Exclusion Criteria -
Required Medical Information For adult medulloblastoma: patient has received chemotherapy previously AND has
tumor(s) with mutations in the sonic hedgehog pathway
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ERLEADA
Drug Names ERLEADA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The requested drug will be used in combination with a gonadotropin-releasing hormone
(GnRH) analog or after bilateral orchiectomy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ERLOTINIB
Drug Names ERLOTINIB HYDROCHLORIDE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent or advanced non-small cell lung cancer (NSCLC), recurrent chordoma,
relapsed or stage IV renal cell carcinoma (RCC), brain metastases from NSCLC.
Exclusion Criteria -
Required Medical Information For NSCLC (including brain metastases from NSCLC): 1) the disease is recurrent,
advanced, or metastatic and 2) the patient has sensitizing EGFR mutation-positive
disease. For pancreatic cancer: the disease is locally advanced, unresectable, or
metastatic.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 32
Prior Authorization Group ESBRIET
Drug Names ESBRIET
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For idiopathic pulmonary fibrosis (Initial Review Only): 1) a high-resolution computed
tomography (HRCT) study of the chest or a lung biopsy reveals the usual interstitial
pneumonia (UIP) pattern, OR 2) HRCT study of the chest reveals a result other than
the UIP pattern (e.g., probable UIP, indeterminate for UIP) and the diagnosis is
supported either by a lung biopsy or by a multidisciplinary discussion between at least
a radiologist and pulmonologist who are experienced in idiopathic pulmonary fibrosis if
a lung biopsy has not been conducted.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group EVEROLIMUS
Drug Names AFINITOR, AFINITOR DISPERZ, EVEROLIMUS
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Classic Hodgkin lymphoma, thymomas and thymic carcinomas, Waldenstrom's
macroglobulinemia/lymphoplasmacytic lymphoma, soft tissue sarcoma (perivascular
epithelioid cell tumors (PEComa) and lymphangioleiomyomatosis subtypes),
gastrointestinal stromal tumors, neuroendocrine tumors of the thymus, thyroid
carcinoma (papillary, Hurthle cell, and follicular), endometrial carcinoma.
Exclusion Criteria -
Required Medical Information For breast cancer: 1) The disease is recurrent or metastatic hormone receptor (HR)-
positive, human epidermal growth factor receptor 2 (HER2)-negative, AND 2) The
requested medication is prescribed in combination with exemestane, fulvestrant, or
tamoxifen, AND 3) The requested medication is used for subsequent treatment. For
renal cell carcinoma: The disease is relapsed, advanced, or stage IV. For
subependymal giant cell astrocytoma (SEGA): The requested drug is given as adjuvant
treatment.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 33
Prior Authorization Group FABRAZYME
Drug Names FABRAZYME
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information Diagnosis of Fabry disease was confirmed by an enzyme assay demonstrating a
deficiency of alpha-galactosidase enzyme activity or by genetic testing, or the patient is
a symptomatic obligate female carrier.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group FANAPT
Drug Names FANAPT, FANAPT TITRATION PACK
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The patient experienced an inadequate treatment response, intolerance, or
contraindication to one of the following generic products: A) aripiprazole, B) asenapine,
C) olanzapine, D) quetiapine, E) risperidone, F) ziprasidone AND the patient
experienced an inadequate treatment response, intolerance, or contraindication to one
of the following brand products: A) Latuda, B) Rexulti, C) Secuado.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group FARYDAK
Drug Names FARYDAK
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 34
Prior Authorization Group FASENRA
Drug Names FASENRA, FASENRA PEN
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For severe asthma: For initial therapy: 1) Either a) Patient has baseline blood
eosinophil count of at least 150 cells per microliter OR b) Patient is dependent on
systemic corticosteroids, and 2) Patient has a history of severe asthma despite current
treatment with both of the following medications at optimized doses: a) inhaled
corticosteroid and b) additional controller (long-acting beta2-agonist, leukotriene
modifier, or sustained-release theophylline). For continuation of therapy: Asthma
control has improved on treatment with the requested drug, as demonstrated by a
reduction in the frequency and/or severity of symptoms and exacerbations or a
reduction in the daily maintenance oral corticosteroid dose.
Age Restrictions 12 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group FENTANYL PATCH
Drug Names FENTANYL
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The requested drug is being prescribed for pain associated with cancer, sickle cell
disease, a terminal condition, or pain being managed through palliative care OR 2) The
requested drug is being prescribed for pain severe enough to require daily, around-the-
clock, long-term treatment in a patient who has been taking an opioid AND 3) The
patient can safely take the requested dose based on their history of opioid use [Note:
This drug should be prescribed only by healthcare professionals who are
knowledgeable in the use of potent opioids for the management of chronic pain.] AND
4) The patient has been evaluated and the patient will be monitored for the
development of opioid use disorder AND 5) This request is for continuation of therapy
for a patient who has been receiving an extended-release opioid agent for at least 30
days OR the patient has taken an immediate-release opioid for at least one week.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 35
Prior Authorization Group FETZIMA
Drug Names FETZIMA, FETZIMA TITRATION PACK
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The patient has experienced an inadequate treatment response, intolerance, or the
patient has a contraindication to TWO of the following: serotonin and norepinephrine
reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs),
mirtazapine, bupropion.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group FINTEPLA
Drug Names FINTEPLA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group FLUCYTOSINE
Drug Names FLUCYTOSINE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 6 weeks
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 36
Prior Authorization Group FORTEO
Drug Names FORTEO
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For postmenopausal osteoporosis: patient has ONE of the following (1 or 2): 1) a
history of fragility fracture, OR 2) A pre-treatment T-score of less than or equal to -2.5
or pre-treatment T-score greater than -2.5 and less than -1 with a high pre-treatment
Fracture Risk Assessment Tool (FRAX) fracture probability AND patient has ANY of the
following: a) indicators for higher fracture risk (e.g., advanced age, frailty, glucocorticoid
therapy, very low T-scores, or increased fall risk), OR b) patient has failed prior
treatment with or is intolerant to a previous injectable osteoporosis therapy OR c)
patient has had an oral bisphosphonate trial of at least 1-year duration or there is a
clinical reason to avoid treatment with an oral bisphosphonate. For primary or
hypogonadal osteoporosis in men: patient has one of the following: 1) a history of
osteoporotic vertebral or hip fracture, OR 2) pre-treatment T-score of less than or equal
to -2.5, OR 3) pre-treatment T-score greater than -2.5 and less than -1 with a high pre-
treatment FRAX fracture probability. For glucocorticoid-induced osteoporosis: Patient
has had an oral bisphosphonate trial of at least 1-year duration unless patient has a
contraindication or intolerance to an oral bisphosphonate, AND patient meets ANY of
the following: 1) patient has a history of fragility fracture, OR 2) a pre-treatment T-score
of less than or equal to -2.5, OR 3) pre-treatment T-score greater than -2.5 and less
than -1 with a high pre-treatment FRAX fracture probability.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 24 months total unless the patient remains at high risk for fracture and benefit
outweighs risk
Other Criteria Patient has high FRAX fracture probability if the 10 year probability is either greater
than or equal to 20 percent for any major osteoporotic fracture or greater than or equal
to 3 percent for hip fracture. If glucocorticoid treatment is greater than 7.5 mg
(prednisone equivalent) per day, the estimated risk score generated with FRAX should
be multiplied by 1.15 for major osteoporotic fracture and 1.2 for hip fracture.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 37
Prior Authorization Group FOTIVDA
Drug Names FOTIVDA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For advanced renal cell carcinoma: The following criteria must be met: 1) The disease
is relapsed or refractory, 2) The requested medication must be used after at least two
prior systemic therapies, and 3) The patient has experienced disease progression or an
intolerable adverse event with a trial of cabozantinib.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group FYCOMPA
Drug Names FYCOMPA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For treatment of partial-onset seizures: 1) The patient experienced an inadequate
treatment response, intolerance, or contraindication to a generic anticonvulsant AND 2)
The patient has experienced an inadequate treatment response, intolerance, or
contraindication to any of the following: Aptiom, Vimpat, Xcopri, Spritam. For adjunctive
treatment of primary generalized tonic-clonic seizures: 1) The patient experienced an
inadequate treatment response, intolerance, or contraindication to a generic
anticonvulsant AND 2) The patient experienced an inadequate treatment response,
intolerance, or contraindication to one of the following: Vimpat, Spritam.
Age Restrictions Partial-onset seizures: 4 years of age or older. Primary generalized tonic-clonic
seizures: 12 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 38
Prior Authorization Group GATTEX
Drug Names GATTEX
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For short bowel syndrome (SBS) initial therapy: Adult patients were dependent on
parenteral support for at least 12 months. For SBS continuation: Requirement for
parenteral support has decreased from baseline while on therapy with the requested
medication.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group GAVRETO
Drug Names GAVRETO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent or advanced rearranged during transfection (RET) rearrangement-positive
non-small cell lung cancer
Exclusion Criteria -
Required Medical Information For non-small cell lung cancer, patient must meet all of the following: 1) The disease is
recurrent, advanced, or metastatic, and 2) The tumor is rearranged during transfection
(RET) fusion-positive or RET rearrangement-positive.
Age Restrictions Non-small cell lung cancer: 18 years of age or older. Medullary thyroid cancer and
thyroid cancer: 12 years of age or older.
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group GILENYA
Drug Names GILENYA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 39
Prior Authorization Group GILOTRIF
Drug Names GILOTRIF
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For non-small cell lung cancer (NSCLC): Patient meets either of the following:
1) Patient has metastatic squamous NSCLC that progressed after platinum-based
chemotherapy, OR 2) Patient has sensitizing EGFR mutation-positive disease.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group GLATIRAMER
Drug Names GLATIRAMER ACETATE, GLATOPA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 40
Prior Authorization Group GROWTH HORMONE
Drug Names GENOTROPIN, GENOTROPIN MINIQUICK
PA Indication Indicator All Medically-accepted Indications
Off-label Uses -
Exclusion Criteria Pediatric patients with closed epiphyses (except in patients with PWS).
Required Medical Information Pediatric growth hormone deficiency (GHD): Patient (pt) meets any of the following: 1)
younger than 2.5 years old (yo) with pre-treatment (pre-tx) height (ht) more than 2
standard deviations (SD) below mean and slow growth velocity OR 2) 2.5 yo or older
AND one of the following: a) pre-tx 1-year ht velocity more than 2 SD below mean OR
b) pre-tx ht more than 2 SD below mean and 1-year ht velocity more than 1 SD below
mean, AND patient meets any of the following: 1) failed 2 pre-tx growth hormone (GH)
stimulation tests (peak below 10 ng/mL), OR 2) pituitary/central nervous system (CNS)
disorder (e.g., genetic defects, CNS tumors, congenital structural abnormalities) and
pre-tx insulin-like growth factor-1 (IGF-1) more than 2 SD below mean, OR 3) pt is a
neonate or was diagnosed with GHD as a neonate. Turner syndrome: 1) Confirmed by
karyotyping AND 2) pre-tx ht is less than the 5th percentile for age. Small for
gestational age (GA): 1) Birth weight (wt) less than 2500g at GA greater than 37 weeks,
OR birth wt or length below 3rd percentile for GA or at least 2 SD below mean for GA,
AND 2) did not manifest catch-up growth by age 2.
Age Restrictions SGA: 2 years of age or older
Prescriber Restrictions Endocrinologist, pediatric endocrinologist, pediatric nephrologist, infectious disease
specialist, gastroenterologist/nutritional support specialist, geneticist.
Coverage Duration Plan Year
Other Criteria Adult GHD: Pt meets any of the following: 1) failed 2 pre-tx GH stimulation tests, OR 2)
pre-tx IGF-1 more than 2 SD below mean AND failed 1 pre-tx GH stimulation test.
(Note: Stimulation tests include: a) insulin tolerance test [ITT] [peak GH less than or
equal to 5 ng/ml], or b) Macrelin-stimulation test [peak GH level less than 2.8ng/ml], or
c) glucagon-stimulation test [GST] [peak GH level less than or equal to 3 ng/ml] for pt
with a body mass index [BMI] 25-30 kg/m2 and high pretest probability of GHD [e.g.,
acquired structural abnormalities] or BMI less than 25 kg/m2, or d) GST [peak GH level
less than or equal to 1 ng/ml] in pt with BMI 25-30 kg/m2 and low pretest probability of
GHD or BMI greater than 30 kg/m2), OR 3) organic hypothalamic-pituitary disease
(e.g., suprasellar mass with previous surgery and cranial irradiation) with 3 or more
pituitary hormone deficiencies AND pre-tx IGF-1 more than 2 SD below mean, OR 4)
genetic or structural hypothalamic-pituitary defects, OR 5) childhood-onset GHD with
congenital (genetic or structural) abnormality of the hypothalamus/pituitary/CNS.
Renewal for pediatric GHD, TS, SGA, and adult GHD: Patient is experiencing
improvement.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 41
Prior Authorization Group HAEGARDA
Drug Names HAEGARDA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The requested drug is being used for the prevention of acute angioedema attacks.
Patient has hereditary angioedema (HAE) with C1 inhibitor deficiency or dysfunction
confirmed by laboratory testing OR patient has hereditary angioedema with normal C1
inhibitor confirmed by laboratory testing. For patients with HAE with normal C1 inhibitor,
EITHER 1) Patient tested positive for an F12, angiopoietin-1, plasminogen, or
kininogen-1 (KNG1) gene mutation OR 2) Patient has a family history of angioedema
and the angioedema was refractory to a trial of an antihistamine for at least one month.
Age Restrictions -
Prescriber Restrictions Immunologist, allergist, rheumatologist
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group HARVONI
Drug Names HARVONI
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For hepatitis C virus (HCV): Infection confirmed by presence of HCV RNA in the serum
prior to starting treatment. Planned treatment regimen, genotype, prior treatment
history, presence or absence of cirrhosis (compensated or decompensated [Child
Turcotte Pugh class B or C]), presence or absence of human immunodeficiency virus
(HIV) coinfection, presence or absence of resistance-associated substitutions where
applicable, liver and kidney transplantation status if applicable. Coverage conditions
and specific durations of approval will be based on current AASLD treatment
guidelines.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Criteria applied consistent w/ current AASLD-IDSA guidance. Reminder for 8wk option
if appropriate.
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 42
Prior Authorization Group HERCEPTIN
Drug Names HERCEPTIN
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, recurrent or advanced unresectable HER2-positive breast cancer,
leptomeningeal metastases from HER2-positive breast cancer, HER2-positive
esophageal and esophagogastric junction cancer, HER2-positive advanced or
recurrent uterine serous carcinoma, HER2-amplified colorectal cancer in combination
with pertuzumab or lapatinib.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Neoadjuvant therapy for breast cancer: 6 months. Other: Plan Year.
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual. The
patient had an intolerable adverse event to Trazimera and that adverse event was NOT
attributed to the active ingredient as described in the prescribing information.
Prior Authorization Group HERCEPTIN HYLECTA
Drug Names HERCEPTIN HYLECTA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, recurrent or advanced unresectable HER2-positive breast cancer.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Neoadjuvant therapy for breast cancer: 6 months, Other: Plan Year.
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 43
Prior Authorization Group HERZUMA
Drug Names HERZUMA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, recurrent or advanced unresectable HER2-positive breast cancer,
leptomeningeal metastases from HER2-positive breast cancer, HER2-positive
esophageal and esophagogastric junction cancer, HER2-positive advanced or
recurrent uterine serous carcinoma, HER2-amplified colorectal cancer in combination
with pertuzumab or lapatinib.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Neoadjuvant therapy for breast cancer: 6 months. Other: Plan Year.
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual. The
patient had an intolerable adverse event to Trazimera and that adverse event was NOT
attributed to the active ingredient as described in the prescribing information.
Prior Authorization Group HETLIOZ
Drug Names HETLIOZ
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For Non-24-Hour Sleep-Wake Disorder: 1) for initial therapy and continuation of
therapy: a) diagnosis of total blindness in both eyes (e.g., nonfunctioning retinas) and
b) unable to perceive light in either eye, AND 2) if currently on therapy with the
requested drug, patient must meet at least one of the following: a) increased total
nighttime sleep or b) decreased daytime nap duration. For nighttime sleep disturbances
in Smith-Magenis Syndrome (SMS): 1) for initial therapy and continuation therapy, the
patient has a confirmed diagnosis of SMS AND 2) if currently on therapy with the
requested drug, the patient experiences improvement in the quality of sleep since
starting therapy.
Age Restrictions Non-24: 18 years of age or older. SMS: 16 years of age or older
Prescriber Restrictions Sleep disorder specialist or neurologist
Coverage Duration Initiation: 6 Months, Renewal: Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 44
Prior Authorization Group HRM-ANTICONVULSANTS
Drug Names PHENOBARBITAL, PHENOBARBITAL SODIUM
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Epilepsy
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
Prior Authorization Group HRM-ANTIPARKINSON
Drug Names BENZTROPINE MESYLATE, TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL
HYDROCHLO
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information EPS (extrapyramidal symptoms): 1) The patient has not tried the non-HRM alternative
drug amantadine AND 2) The patient has a contraindication to the non-HRM alternative
drug amantadine OR 3) The patient has tried the non-HRM alternative drug
amantadine AND 4) The patient experienced an inadequate treatment response OR
intolerance to the non-HRM alternative drug amantadine. Parkinson's: 1) The patient
has tried two of the following non-HRM alternative drugs: amantadine,
carbidopa/levodopa, pramipexole, or ropinirole. AND 2) The patient experienced an
inadequate treatment response OR intolerance to two of the following non-HRM
alternative drugs: amantadine, carbidopa/levodopa, pramipexole, or ropinirole.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 45
Prior Authorization Group HRM-CYPROHEPTADINE
Drug Names CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLOR
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Pruritus, spasticity due to spinal cord injury
Exclusion Criteria -
Required Medical Information For rhinitis: 1) The patient has tried two of the following non-HRM alternative drugs:
levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal AND 2) The
patient experienced an inadequate treatment response OR intolerance to two of the
following non-HRM alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal,
or flunisolide nasal.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) The prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
Prior Authorization Group HRM-DIPYRIDAMOLE
Drug Names DIPYRIDAMOLE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 46
Prior Authorization Group HRM-GUANFACINE ER
Drug Names GUANFACINE ER, GUANFACINE HYDROCHLORIDE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
Prior Authorization Group HRM-GUANFACINE IR
Drug Names GUANFACINE HCL
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 47
Prior Authorization Group HRM-HYDROXYZINE
Drug Names HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE
PAMOATE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For anxiety: 1) The patient has tried two of the following alternative drugs: buspirone,
duloxetine, escitalopram, sertraline, or venlafaxine extended-release AND 2) The
patient experienced an inadequate treatment response OR intolerance to two of the
following alternative drugs: buspirone, duloxetine, escitalopram, sertraline, or
venlafaxine extended-release OR 3) The patient has not tried two of the following
alternative drugs: buspirone, duloxetine, escitalopram, sertraline or venlafaxine
extended-release AND 4) The patient has acute anxiety. If the patient is taking one or
more additional anticholinergic medications (e.g., oxybutynin, meclizine, paroxetine,
amitriptyline, dicyclomine, cyclobenzaprine) with the requested drug, the prescriber has
determined that taking multiple anticholinergic medications is medically necessary for
the patient [Note: Use of multiple anticholinergic medications in older adults is
associated with an increased risk of cognitive decline.].
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 48
Prior Authorization Group HRM-HYDROXYZINE INJ
Drug Names HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information Alcohol Withdrawal Syndrome: 1) The patient has not tried one of the following
alternative drugs: clorazepate or lorazepam AND 2) The patient has a contraindication
to one of the following alternative drugs: clorazepate or lorazepam OR 3) The patient
has tried one of the following alternative drugs: clorazepate or lorazepam AND 4) The
patient experienced an inadequate treatment response OR intolerance to one of the
following alternative drugs: clorazepate or lorazepam. Anxiety: 1) The patient has tried
two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline or
venlafaxine extended-release AND 2) The patient experienced an inadequate
treatment response OR intolerance to two of the following alternative drugs: buspirone,
duloxetine, escitalopram, sertraline or venlafaxine extended-release OR 3) The patient
has not tried two of the following alternative drugs: buspirone, duloxetine, escitalopram,
sertraline or venlafaxine extended-release AND 4) The patient has acute anxiety.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 49
Prior Authorization Group HRM-HYPNOTICS
Drug Names ESZOPICLONE, ZALEPLON, ZOLPIDEM TARTRATE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The patient has a contraindication to the non-HRM (non-High Risk Medication)
alternative drug doxepin (3 mg or 6 mg) OR 2) The non-HRM (non-High Risk
Medication) alternative drug doxepin (3 mg or 6 mg) has been tried AND 3) The patient
experienced an inadequate treatment response OR intolerance to the non-HRM (non-
High Risk Medication) alternative drug doxepin (3 mg or 6 mg) AND 4) If the patient is
using two or more additional central nervous system (CNS) active medications (e.g.,
lorazepam, quetiapine, sertraline, clonazepam, escitalopram, alprazolam) with the
requested drug, the prescriber has determined that taking multiple central nervous
system (CNS) active medications is medically necessary for the patient [Note: Use of
multiple central nervous system (CNS) active medications in older adults is associated
with an increased risk of falls.].
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient. APPLIES TO GREATER THAN CUMULATIVE 90 DAYS OF THERAPY PER
YEAR.
Prior Authorization Group HRM-METHYLDOPA
Drug Names METHYLDOPA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 50
Prior Authorization Group HRM-PROMETHAZINE
Drug Names PROMETHAZINE HCL, PROMETHAZINE HCL PLAIN, PROMETHAZINE
HYDROCHLORID
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For rhinitis: 1) The patient has tried two of the following non-HRM alternative drugs:
levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal AND 2) The
patient experienced an inadequate treatment response OR intolerance to two of the
following non-HRM alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal,
or flunisolide nasal.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
Prior Authorization Group HRM-SCOPOLAMINE
Drug Names SCOPOLAMINE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Excessive salivation
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 51
Prior Authorization Group HRM-SKELETAL MUSCLE RELAXANTS
Drug Names CARISOPRODOL, CYCLOBENZAPRINE HYDROCHLO, METHOCARBAMOL,
VANADOM
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information If the patient is using one or more additional anticholinergic medications (e.g.,
oxybutynin, meclizine, paroxetine, amitriptyline, dicyclomine, hydroxyzine) with the
requested drug, the prescriber has determined that taking multiple anticholinergic
medications is medically necessary for the patient [Note: Use of multiple anticholinergic
medications in older adults is associated with an increased risk of cognitive decline.].
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 3 months
Other Criteria This Prior Authorization requirement only applies to patients 70 years of age or older.
(The American Geriatrics Society identifies the use of this medication as potentially
inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage,
or used with caution or carefully monitored.) Prescriber must acknowledge that the
benefit of therapy with this prescribed medication outweighs the potential risks for this
patient.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 52
Prior Authorization Group HUMIRA
Drug Names HUMIRA, HUMIRA PEDIATRIC CROHNS D, HUMIRA PEN, HUMIRA PEN-CD/UC/HS
START, HUMIRA PEN-PEDIATRIC UC S, HUMIRA PEN-PS/UV STARTER
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Axial spondyloarthritis, Behcet's syndrome
Exclusion Criteria -
Required Medical Information For moderately to severely active rheumatoid arthritis (new starts only): 1) Inadequate
response, intolerance or contraindication to methotrexate (MTX) OR 2) Inadequate
response or intolerance to a prior biologic disease-modifying antirheumatic drug
(DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis and axial
spondyloarthritis (new starts only): 1) Inadequate response to a non-steroidal anti-
inflammatory drug (NSAID) trial OR 2) Intolerance or contraindication to NSAIDs. For
moderate to severe plaque psoriasis (new starts only): 1) At least 3% of body surface
area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin,
intertriginous areas) are affected at the time of diagnosis, AND 2) Patient meets any of
the following: a) Patient has experienced an inadequate response or intolerance to
either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate,
cyclosporine, or acitretin, OR b) Pharmacologic treatment with methotrexate,
cyclosporine, or acitretin is contraindicated, OR c) Patient has severe psoriasis that
warrants a biologic DMARD as first-line therapy (i.e. at least 10% of the BSA or crucial
body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are
affected). For moderately to severely active Crohn's disease (new starts only): 1)
Inadequate response to at least one conventional therapy (e.g., corticosteroids), OR 2)
Intolerance or contraindication to conventional therapy. For moderately to severely
active ulcerative colitis (new starts only): 1) Inadequate response to at least one
conventional therapy (e.g., corticosteroids), OR 2) Intolerance or contraindication to
conventional therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 53
Prior Authorization Group HYPNOTIC BENZODIAZEPINES
Drug Names TEMAZEPAM
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information Prescriber must acknowledge the benefit of therapy with the requested drug outweighs
the potential risks for the patient. (Note: The American Geriatrics Society identifies the
use of this medication as potentially inappropriate in older adults, meaning it is best
avoided, prescribed at reduced dosage, or used with caution or carefully monitored.)
The patient has experienced an inadequate treatment response, intolerance, or has a
contraindication to doxepin (3 mg or 6 mg).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 65 years of age or older.
APPLIES TO GREATER THAN CUMULATIVE 90 DAYS OF THERAPY PER YEAR.
Prior Authorization Group IBRANCE
Drug Names IBRANCE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Unresectable well-differentiated/dedifferentiated liposarcoma of the retroperitoneum.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 54
Prior Authorization Group ICATIBANT
Drug Names ICATIBANT ACETATE, SAJAZIR
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For hereditary angioedema (HAE): The requested drug is being used for the treatment
of acute angioedema attacks. Patient has HAE with C1 inhibitor deficiency or
dysfunction confirmed by laboratory testing OR patient has HAE with normal C1
inhibitor confirmed by laboratory testing. For patients with HAE with normal C1 inhibitor,
EITHER 1) Patient tested positive for an F12, angiopoietin-1, plasminogen, or
kininogen-1 (KNG1) gene mutation OR 2) Patient has a family history of angioedema
and the angioedema was refractory to a trial of an antihistamine for at least one month.
Age Restrictions 18 years of age or older
Prescriber Restrictions Immunologist, allergist, rheumatologist
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ICLUSIG
Drug Names ICLUSIG
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Therapy after hematopoietic stem cell transplant (HSCT) for chronic myeloid leukemia
(CML) and acute lymphoblastic leukemia (ALL) patients
Exclusion Criteria -
Required Medical Information For chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL): diagnosis
was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene. For
CML, including patients who have received a hematopoietic stem cell transplant: 1)
patient has accelerated or blast phase CML and no other kinase inhibitor is indicated,
OR 2) patient has chronic phase CML and has experienced resistance or intolerance to
at least 2 prior kinase inhibitors AND at least one of those was imatinib or dasatinib,
OR 3) patient is positive for the T315I mutation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 55
Prior Authorization Group IDHIFA
Drug Names IDHIFA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Newly-diagnosed acute myeloid leukemia
Exclusion Criteria -
Required Medical Information For acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation:
1) patient has a physiologic age of 60 years or older with newly-diagnosed AML and
meets one of the following: a) patient is not a candidate for intensive induction therapy,
or b) patient declines intensive induction chemotherapy, OR 2) patient has a
physiologic age of 60 years or older and the requested drug will be used as post-
induction therapy following response to induction therapy with the requested drug OR
3) patient has relapsed or refractory AML.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group IMATINIB
Drug Names IMATINIB MESYLATE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Desmoid tumors, pigmented villonodular synovitis/tenosynovial giant cell tumor
(PVNS/TGCT), recurrent chordoma, melanoma, AIDS-related Kaposi sarcoma, chronic
myelomonocytic leukemia, chronic graft versus host disease (cGVHD), T-cell acute
lymphoblastic leukemia, aggressive systemic mastocytosis when eosinophilia is
present with FIP1L1-PDGFRA fusion gene
Exclusion Criteria -
Required Medical Information For chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute
lymphoblastic leukemia (Ph+ ALL): diagnosis was confirmed by detection of the
Philadelphia chromosome or BCR-ABL gene. For CML: patient did not fail (excluding
failure due to intolerance) prior therapy with a tyrosine kinase inhibitor. For melanoma:
c-Kit mutation is positive.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 56
Prior Authorization Group IMBRUVICA
Drug Names IMBRUVICA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Hairy cell leukemia, lymphoplasmacytic lymphoma, follicular lymphoma, primary central
nervous system lymphoma, AIDS-related B-cell lymphoma, histologic transformation of
nodal marginal zone lymphoma to diffuse large B-cell lymphoma, diffuse large B-cell
lymphoma, post-transplant lymphoproliferative disorders, high-grade B-cell lymphoma.
Exclusion Criteria -
Required Medical Information For mantle cell lymphoma: 1) the requested drug will be used in a patient who has
received at least one prior therapy, OR 2) the requested drug will be used in
combination with rituximab as pretreatment to induction therapy with RHyperCVAD
(rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen.
For marginal zone lymphoma (including gastric mucosa-associated lymphoid tissue
[MALT] lymphoma, non-gastric MALT lymphoma, nodal marginal zone lymphoma, and
splenic marginal zone lymphoma): the patient has received at least one prior therapy.
For hairy cell leukemia: the requested drug will be used as a single agent for disease
progression. For primary central nervous system lymphoma: 1) the disease is relapsed
or refractory OR 2) the requested drug is used for induction therapy as a single agent.
For histologic transformation of nodal marginal zone lymphoma to diffuse large B-cell
lymphoma: the requested drug will be used in patients who have received prior
chemoimmunotherapy. For diffuse large B-cell lymphoma: the requested drug will be
used as second-line or subsequent therapy. For AIDS-related B-cell lymphoma: the
requested drug will be used as a single agent and as second-line or subsequent
therapy for relapsed disease. For post-transplant lymphoproliferative disorders: the
requested drug will be used in patients who have received prior chemoimmunotherapy.
For high-grade B-cell lymphoma: the requested drug will be used as second-line or
subsequent therapy. For follicular lymphoma: the requested drug will be used as a
single agent.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 57
Prior Authorization Group INCRELEX
Drug Names INCRELEX
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria Pediatric patients with closed epiphyses
Required Medical Information For growth failure due to severe primary insulin-like growth factor-1 (IGF-1) deficiency
or growth hormone gene deletion in patients who have developed neutralizing
antibodies to growth hormone, must meet all of the following prior to beginning therapy
with the requested drug (new starts only): 1) height 3 or more standard deviations (SD)
below the mean for children of the same age and gender AND 2) basal IGF-1 level 3 or
more SD below the mean for children of the same age and gender AND 3) provocative
growth hormone test showing a normal or elevated growth hormone level. For renewal,
patient is experiencing improvement.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group INGREZZA
Drug Names INGREZZA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group INLYTA
Drug Names INLYTA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Thyroid carcinoma (papillary, Hurthle cell, or follicular).
Exclusion Criteria -
Required Medical Information For renal cell carcinoma: the disease is advanced, relapsed, or stage IV.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 58
Prior Authorization Group INQOVI
Drug Names INQOVI
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group INREBIC
Drug Names INREBIC
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and janus kinase 2
(JAK2) rearrangement
Exclusion Criteria -
Required Medical Information For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and JAK2
rearrangement: the disease is in chronic or blast phase.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 59
Prior Authorization Group IR BEFORE ER
Drug Names HYDROCODONE BITARTRATE ER, HYSINGLA ER, METHADONE HCL,
METHADONE HYDROCHLORIDE I, MORPHINE SULFATE ER, OXYCONTIN
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The requested drug is being prescribed for pain associated with cancer, sickle cell
disease, a terminal condition, or pain being managed through palliative care OR 2) The
requested drug is being prescribed for pain severe enough to require daily, around-the-
clock, long-term treatment in a patient who has been taking an opioid AND 3) The
patient can safely take the requested dose based on their history of opioid use [Note:
This drug should be prescribed only by healthcare professionals who are
knowledgeable in the use of potent opioids for the management of chronic pain.] AND
4) The patient has been evaluated and the patient will be monitored for the
development of opioid use disorder AND 5) This request is for continuation of therapy
for a patient who has been receiving an extended-release opioid agent for at least 30
days OR the patient has taken an immediate-release opioid for at least one week.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group IRESSA
Drug Names IRESSA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Sensitizing epidermal growth factor receptor (EGFR) mutation-positive recurrent or
advanced non-small cell lung cancer (NSCLC).
Exclusion Criteria -
Required Medical Information For NSCLC: 1) disease must be metastatic, advanced, or recurrent and 2) patient must
have a sensitizing EGFR mutation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 60
Prior Authorization Group ISOTRETINOIN
Drug Names ACCUTANE, AMNESTEEM, CLARAVIS, ISOTRETINOIN, MYORISAN, ZENATANE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Refractory acne vulgaris, severe refractory rosacea, neuroblastoma, cutaneous T-cell
lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), high risk for developing
skin cancer (squamous cell cancers), transient acantholytic dermatosis (Grover's
Disease), keratosis follicularis (Darier Disease), lamellar ichthyosis, pityriasis rubra
pilaris.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ITRACONAZOLE
Drug Names ITRACONAZOLE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Coccidioidomycosis, Coccidioidomycosis prophylaxis in HIV infection, Cryptococcosis,
Histoplasmosis prophylaxis in HIV infection, invasive fungal infection prophylaxis in
liver transplant patients, Microsporidiosis, Talaromycosis (formerly Penicilliosis),
Pityriasis versicolor/Tinea versicolor, Sporotrichosis, Tinea corporis, Tinea cruris, Tinea
capitis, Tinea manuum, Tinea pedis
Exclusion Criteria -
Required Medical Information If for the treatment of onychomycosis due to dermatophytes (Tinea unguium), the
diagnosis has been confirmed by a fungal diagnostic test (e.g., potassium hydroxide
[KOH] preparation, fungal culture, or nail biopsy).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Disseminated/CNS histoplasmosis, Histoplasmosis/Coccidioidomycosis ppx: 12 mths.
Others: 6 mths
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 61
Prior Authorization Group IVIG
Drug Names BIVIGAM, FLEBOGAMMA DIF, GAMMAGARD LIQUID, GAMMAGARD S/D IGA LESS
TH, GAMMAKED, GAMMAPLEX, GAMUNEX-C, OCTAGAM, PANZYGA, PRIVIGEN
PA Indication Indicator All Medically-accepted Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For B-cell chronic lymphocytic leukemia (CLL): 1) serum IgG less than 500 mg/dL OR
2) a history of recurrent bacterial infections. For bone marrow transplant/hematopoietic
stem cell transplant (BMT/HSCT): IVIG is requested within the first 100 days post-
transplant OR
1)
2) serum IgG less than 400 mg/dL. For pediatric human
immunodeficiency virus (HIV) infection: 1) serum IgG less than 400 mg/dL, OR 2)
history of recurrent bacterial infections. For dermatomyositis and polymyositis: 1) at
least one standard first-line treatment (corticosteroid or immunosuppressant) has been
tried but was unsuccessful or not tolerated OR 2) patient is unable to receive standard
therapy because of a contraindication or other clinical reason. For pure red cell aplasia
(PRCA): PRCA is secondary to parvovirus B19 infection.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 62
Prior Authorization Group JAKAFI
Drug Names JAKAFI
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Lower-risk myelofibrosis, accelerated phase myelofibrosis, blast phase
myelofibrosis/acute myeloid leukemia, acute lymphoblastic leukemia (ALL), chronic
graft-versus-host disease, chronic myelomonocytic leukemia (CMML)-2, BCR-ABL
negative atypical chronic myeloid leukemia (aCML), essential thrombocythemia, and
myeloid, lymphoid or mixed lineage neoplasms with eosinophilia and JAK2
rearrangement
Exclusion Criteria -
Required Medical Information For polycythemia vera: patient had an inadequate response or intolerance to interferon
therapy or hydroxyurea. For acute lymphoblastic leukemia: patient has a cytokine
receptor-like factor 2 (CRLF2) mutation or a mutation associated with activation of the
Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway.
For CMML-2: the requested drug is used in combination with a hypomethylating agent.
For BCR-ABL negative aCML: the requested drug is used as a single agent or in
combination with a hypomethylating agent. For essential thrombocythemia: patient had
an inadequate response or loss of response to hydroxyurea, interferon therapy, or
anagrelide. For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and
JAK2 rearrangement: the disease is in chronic or blast phase.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group KALYDECO
Drug Names KALYDECO
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For cystic fibrosis (CF): The requested medication will not be used in combination with
other medications containing ivacaftor.
Age Restrictions 4 months of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 63
Prior Authorization Group KANJINTI
Drug Names KANJINTI
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, recurrent or advanced unresectable HER2-positive breast cancer,
leptomeningeal metastases from HER2-positive breast cancer, HER2-positive
esophageal and esophagogastric junction cancer, HER2-positive advanced or
recurrent uterine serous carcinoma, HER2-amplified colorectal cancer in combination
with pertuzumab or lapatinib.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Neoadjuvant therapy for breast cancer: 6 months. Other: Plan Year.
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual. The
patient had an intolerable adverse event to Trazimera and that adverse event was NOT
attributed to the active ingredient as described in the prescribing information.
Prior Authorization Group KETOCONAZOLE
Drug Names KETOCONAZOLE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Cushing's syndrome
Exclusion Criteria Acute or chronic liver disease. Concurrent use with drugs that are contraindicated with
ketoconazole tablets: dofetilide, quinidine, pimozide, cisapride, methadone,
disopyramide, dronedarone, ranolazine, ergot alkaloids, irinotecan, lurasidone, oral
midazolam, alprazolam, triazolam, felodipine, nisoldipine, tolvaptan, eplerenone,
lovastatin, simvastatin, or colchicine.
Required Medical Information The potential benefits outweigh the risks of treatment with oral ketoconazole. For
systemic fungal infections, the patient has any of the following diagnoses:
blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, or
paracoccidioidomycosis. For Cushing's syndrome: the requested drug is being
prescribed for a patient who cannot tolerate surgery or where surgery has not been
curative.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 6 months
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 64
Prior Authorization Group KEYTRUDA
Drug Names KEYTRUDA
PA Indication Indicator All Medically-accepted Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group KISQALI
Drug Names KISQALI, KISQALI FEMARA 200 DOSE, KISQALI FEMARA 400 DOSE, KISQALI
FEMARA 600 DOSE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria For treatment of breast cancer using Kisqali (ribociclib) in combination with an
aromatase inhibitor or Kisqali Femara Co-Pack (ribociclib and letrozole) as initial
endocrine-based therapy, one the following criteria must be met: 1) the patient is pre-
or peri-menopausal, OR 2) the patient is postmenopausal and the patient has
experienced an intolerable adverse event to Ibrance (palbociclib) AND Verzenio
(abemaciclib) or has a contraindication to Ibrance (palbociclib) AND Verzenio
(abemaciclib). For treatment of breast cancer with Kisqali (ribociclib) in combination
with fulvestrant, one of the following criteria must met: 1) the requested drug is being
used with fulvestrant as initial endocrine-based therapy in a postmenopausal patient,
OR 2) the requested drug is being used following disease progression on endocrine
therapy in a postmenopausal patient and the patient has experienced an intolerable
adverse event to Ibrance (palbociclib) AND Verzenio (abemaciclib) OR has a
contraindication to Ibrance (palbociclib) AND Verzenio (abemaciclib).
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 65
Prior Authorization Group KORLYM
Drug Names KORLYM
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions Endocrinologist
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group KYNMOBI
Drug Names KYNMOBI
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For continuation treatment of off episodes in Parkinson's disease: The patient is
experiencing improvement on the requested drug.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group LAPATINIB
Drug Names LAPATINIB DITOSYLATE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Brain metastases from human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, recurrent epidermal growth factor receptor (EGFR)-positive chordoma,
HER2-amplified and RAS and BRAF wild-type colorectal cancer in combination with
trastuzumab.
Exclusion Criteria -
Required Medical Information For HER2-positive breast cancer, the requested drug will be used in combination with
any of the following: 1) aromatase inhibitor, 2) capecitabine, OR 3) trastuzumab.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 66
Prior Authorization Group LENVIMA
Drug Names LENVIMA 10 MG DAILY DOSE, LENVIMA 12MG DAILY DOSE, LENVIMA 14 MG
DAILY DOSE, LENVIMA 18 MG DAILY DOSE, LENVIMA 20 MG DAILY DOSE,
LENVIMA 24 MG DAILY DOSE, LENVIMA 4 MG DAILY DOSE, LENVIMA 8 MG DAILY
DOSE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Medullary thyroid carcinoma, recurrent endometrial carcinoma
Exclusion Criteria -
Required Medical Information For differentiated thyroid cancer (follicular, papillary, or Hurthle cell): disease is not
amenable to radioactive iodine therapy and unresectable, locally recurrent, persistent,
or metastatic. For hepatocellular carcinoma: disease is unresectable or inoperable,
local, metastatic or with extensive liver tumor burden. For renal cell carcinoma: disease
is advanced, relapsed, or stage IV. For endometrial carcinoma, the patient meets ALL
of the following: 1) The disease is advanced or recurrent, 2) The disease is not
microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), 3) The
patient experienced disease progression following prior systemic therapy, AND 4) The
patient is not a candidate for curative surgery or radiation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group LEUPROLIDE
Drug Names LEUPROLIDE ACETATE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Use in combination with growth hormone for children with growth failure and advancing
puberty, recurrent androgen receptor positive salivary gland tumors.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 67
Prior Authorization Group LIDOCAINE PATCHES
Drug Names LIDOCAINE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Pain associated with diabetic neuropathy, pain associated with cancer-related
neuropathy (including treatment-related neuropathy [e.g., neuropathy associated with
radiation treatment or chemotherapy]).
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group LONSURF
Drug Names LONSURF
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For colorectal cancer: The disease is advanced or metastatic. For gastric or
gastroesophageal junction adenocarcinoma, all of the following criteria must be met: 1)
The disease is unresectable locally advanced, recurrent, or metastatic, and 2) The
patient has been previously treated with at least two prior lines of chemotherapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group LORBRENA
Drug Names LORBRENA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Anaplastic lymphoma kinase (ALK)-positive recurrent or advanced non-small cell lung
cancer (NSCLC) following progression on A) crizotinib as the first ALK therapy and
subsequent therapy with crizotinib in patients with asymptomatic disease or isolated
lesions, or B) brigatinib as the first ALK inhibitor therapy. Repressor of silencing (ROS)-
1 rearrangement-positive recurrent, advanced, or metastatic NSCLC following
progression on crizotinib, entrectinib, or ceritinib.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 68
Prior Authorization Group LUMAKRAS
Drug Names LUMAKRAS
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group LUMIZYME
Drug Names LUMIZYME
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information Diagnosis of Pompe disease was confirmed by an enzyme assay demonstrating a
deficiency of acid alpha-glucosidase (GAA) enzyme activity or by genetic testing.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group LUPRON PED
Drug Names LUPRON DEPOT-PED (1-MONTH, LUPRON DEPOT-PED (3-MONTH
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For central precocious puberty (CPP), patients not currently receiving therapy must
meet all of the following criteria: 1) Diagnosis of CPP was confirmed by a pubertal
response to a gonadotropin releasing hormone (GnRH) agonist test OR a pubertal level
of a third generation luteinizing hormone (LH) assay, 2) Assessment of bone age
versus chronological age supports the diagnosis of CPP, and 3) The onset of
secondary sexual characteristics occurred prior to 8 years of age for female patients
OR prior to 9 years of age for male patients.
Age Restrictions CPP: Patient must be less than 12 years old if female and less than 13 years old if
male.
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 69
Prior Authorization Group LUPRON-ENDOMETRIOSIS
Drug Names LUPRON DEPOT (1-MONTH), LUPRON DEPOT (3-MONTH)
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Breast cancer, malignant sex cord-stromal tumors, epithelial ovarian cancer/fallopian
tube cancer/primary peritoneal cancer
Exclusion Criteria -
Required Medical Information For uterine fibroids, patient must meet one of the following: 1) Diagnosis of anemia
(e.g., hematocrit less than or equal to 30 percent and/or hemoglobin less than or equal
to 10g/dL), OR 2) the requested medication will be used prior to surgery for uterine
fibroids.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Fibroids: 3 months (mo), max 6 mo total. Endometriosis: 6 mo, max 12 mo total.
Others: Plan Year
Other Criteria -
Prior Authorization Group LYNPARZA
Drug Names LYNPARZA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent HER2-negative, BRCA 1/2-germline mutated breast cancer, recurrent or
metastatic HER2-positive, BRCA 1/2-germline mutated breast cancer
Exclusion Criteria -
Required Medical Information For breast cancer the disease must be: 1) BRCA 1/2-germline mutated, and 2)
recurrent or metastatic. For prostate cancer: The patient has progressed on prior
treatment with an androgen receptor-directed therapy. For epithelial ovarian, fallopian
tube, or primary peritoneal cancer: 1) The requested drug is used for maintenance
therapy for stage II-IV or recurrent disease who are in complete or partial response to
chemotherapy OR 2) The patient has deleterious or suspected deleterious germline
BRCA-mutated advanced, recurrent, or persistent disease after two or more prior
chemotherapy regimens.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 70
Prior Authorization Group LYRICA CR
Drug Names PREGABALIN ER
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The patient has experienced an inadequate treatment response to gabapentin, or the
patient has experienced an intolerance to gabapentin, or the patient has a
contraindication to gabapentin.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group MAVYRET
Drug Names MAVYRET
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria Decompensated cirrhosis/moderate or severe hepatic impairment (Child Turcotte Pugh
[CTP] class B or C).
Required Medical Information For hepatitis C virus (HCV): Infection confirmed by presence of HCV RNA in the serum
prior to starting treatment. Planned treatment regimen, genotype, prior treatment
history, presence or absence of cirrhosis (compensated or decompensated [CTP class
B or C]), presence or absence of human immunodeficiency virus (HIV) coinfection,
presence or absence of resistance-associated substitutions where applicable, liver and
kidney transplantation status if applicable. Coverage conditions and specific durations
of approval will be based on current American Association for the Study of Liver
Diseases (AASLD) treatment guidelines.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Criteria will be applied consistent with current AASLD-IDSA guidance
Other Criteria -
Prior Authorization Group MEGESTROL
Drug Names MEGESTROL ACETATE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Cancer-related cachexia in adults
Exclusion Criteria -
Required Medical Information Patient has experienced an inadequate treatment response or intolerance to megestrol
40 mg/mL oral suspension.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 71
Prior Authorization Group MEKINIST
Drug Names MEKINIST
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Brain metastases from melanoma, uveal melanoma, central nervous system (CNS)
cancer (i.e., glioma, meningioma, astrocytoma), low grade serous ovarian cancer.
Exclusion Criteria -
Required Medical Information For brain metastasis from melanoma, adjuvant treatment of melanoma, and central
nervous system (CNS) cancer (i.e., glioma, meningioma, astrocytoma): 1) The tumor is
positive for a BRAF V600 activating mutation (e.g., V600E or V600K), and 2) The
requested drug will be used in combination with dabrafenib. For unresectable or
metastatic melanoma: 1) The tumor is positive for a BRAF V600 activating mutation
(e.g., V600E or V600K), and 2) The requested drug will be used as a single agent or in
combination with dabrafenib. For non-small cell lung cancer, and anaplastic thyroid
cancer: 1) The tumor is positive for a BRAF V600E mutation, and 2) The requested
drug will be used in combination with dabrafenib. For uveal melanoma, the requested
drug will be used as a single agent. For low grade serous ovarian cancer: The
requested drug will be used to treat persistent or recurrent disease.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group MEKTOVI
Drug Names MEKTOVI
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Adjuvant systemic therapy for cutaneous melanoma
Exclusion Criteria -
Required Medical Information For cutaneous melanoma: The patient must meet all of the following criteria: 1) Tumor
is positive for BRAF V600 activating mutation (e.g., V600E or V600K), 2) The
requested drug will be used in combination with encorafenib, and 3) The requested
drug will be used for either of the following: a) unresectable or metastatic disease, or b)
adjuvant systemic therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 72
Prior Authorization Group MEMANTINE
Drug Names MEMANTINE HCL TITRATION P, MEMANTINE HYDROCHLORIDE, MEMANTINE
HYDROCHLORIDE E
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This edit only applies to patients less than 30 years of age.
Prior Authorization Group METHYLPHENIDATE
Drug Names METADATE ER, METHYLPHENIDATE HYDROCHLO
PA Indication Indicator All Medically-accepted Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or
Attention Deficit Disorder (ADD) OR 2) The patient has a diagnosis of narcolepsy
confirmed by a sleep study OR 3) The requested drug is being prescribed for the
treatment of cancer-related fatigue after other causes of fatigue have been ruled out.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group MIGLUSTAT
Drug Names MIGLUSTAT
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For Gaucher disease: the diagnosis was confirmed by an enzyme assay demonstrating
a deficiency of beta-glucocerebrosidase enzyme activity or by genetic testing.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 73
Prior Authorization Group MONJUVI
Drug Names MONJUVI
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group MVASI
Drug Names MVASI
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Breast cancer, central nervous system (CNS) tumor types: adult low-grade (WHO
Grade II) infiltrative supratentorial astrocytoma/oligodendroglioma, adult intracranial
and spinal ependymoma, anaplastic gliomas, adult medulloblastoma, primary central
nervous system lymphoma, meningiomas, limited and extensive brain metastases,
metastatic spine tumors, malignant pleural mesothelioma, epithelial ovarian
cancer/fallopian tube cancer/primary peritoneal cancer, including the following cancer
types: carcinosarcoma (malignant mixed Mullerian tumors), clear cell carcinoma,
mucinous carcinoma, grade 1 endometrioid carcinoma, low-grade serous carcinoma,
ovarian borderline epithelial tumors (low malignant potential) with invasive implants,
and malignant sex cord-stromal tumors, soft tissue sarcoma types: angiosarcoma and
solitary fibrous tumor/hemangiopericytoma, uterine neoplasms, endometrial carcinoma,
vulvar squamous cell carcinoma, and ophthalmic-related disorders: diabetic macular
edema, neovascular (wet) age-related macular degeneration including polypoidal
choroidopathy and retinal angiomatous proliferation subtypes, macular edema following
retinal vein occlusion, proliferative diabetic retinopathy, choroidal neovascularization,
neovascular glaucoma and retinopathy of prematurity, hepatocellular carcinoma, small
bowel adenocarcinoma.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 74
Prior Authorization Group NAGLAZYME
Drug Names NAGLAZYME
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For mucopolysaccharidosis VI disease: Diagnosis was confirmed by an enzyme assay
demonstrating a deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B)
enzyme activity or by genetic testing.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group NATPARA
Drug Names NATPARA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria Acute postsurgical hypoparathyroidism (within 6 months of surgery) and expected
recovery from hypoparathyroidism.
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group NERLYNX
Drug Names NERLYNX
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer,
Brain metastases from HER2-positive breast cancer.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 75
Prior Authorization Group NEXAVAR
Drug Names NEXAVAR
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Acute myeloid leukemia, soft tissue sarcoma (angiosarcoma, desmoid
tumors/aggressive fibromatosis, and solitary fibrous tumor subtypes), gastrointestinal
stromal tumor, medullary thyroid carcinoma, osteosarcoma, recurrent chordoma,
epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer.
Exclusion Criteria -
Required Medical Information For thyroid carcinoma: Histology is follicular, papillary, Hurthle cell or medullary. For
acute myeloid leukemia, any of the following criteria must be met: 1) The requested
drug is used in combination with azacitidine or decitabine for low-intensity treatment
induction or post-induction therapy AND the patient is 60 years of age or older with
FLT3-ITD mutation, OR 2) The disease is relapsed/refractory AND the requested drug
is a component of repeating the initial successful induction if late relapse (greater than
or equal to 12 months), OR 3) The disease is relapsed/refractory AND the requested
drug is used in combination with azacitidine or decitabine if the patient is FLT3-ITD
mutation positive. For renal cell carcinoma, the patient meets ALL of the following: 1)
The disease is advanced, AND 2) The patient has experienced disease progression or
an intolerable adverse event with a trial of cabozantinib or axitinib.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group NINLARO
Drug Names NINLARO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Systemic light chain amyloidosis, Waldenstrom macroglobulinemia/lymphoplasmacytic
lymphoma
Exclusion Criteria -
Required Medical Information For multiple myeloma: The requested drug will be used in combination with
lenalidomide and dexamethasone OR pomalidomide and dexamethasone OR
dexamethasone OR cyclophosphamide and dexamethasone OR as a single agent.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 76
Prior Authorization Group NITISINONE
Drug Names NITISINONE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For hereditary tyrosinemia type 1: Diagnosis of hereditary tyrosinemia type 1 is
confirmed by one of the following: 1) biochemical testing (e.g., detection of
succinylacetone in urine) or 2) DNA testing (mutation analysis).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group NORTHERA
Drug Names DROXIDOPA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For neurogenic orthostatic hypotension (nOH): Prior to initial therapy, patient has a
persistent, consistent decrease in systolic blood pressure of at least 20 mmHg OR
decrease in diastolic blood pressure of at least 10 mmHg within 3 minutes of standing
or head-up tilt test. For continuation of therapy for nOH, patient experienced benefit
from therapy (e.g., a sustained decrease in dizziness, lightheadedness, or feeling faint).
For both initial and continuation of therapy for nOH, the requested drug will be used for
patients with neurogenic orthostatic hypotension associated with one of the following
diagnoses: 1) Primary autonomic failure due to Parkinson's disease, multiple system
atrophy, or pure autonomic failure, OR 2) Dopamine beta-hydroxylase deficiency, OR
3) Non-diabetic autonomic neuropathy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 3 months
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 77
Prior Authorization Group NOXAFIL SUSP
Drug Names NOXAFIL
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The requested drug will be used orally. For treatment of oropharyngeal candidiasis:
patient has experienced an inadequate treatment response, intolerance, or has a
contraindication to fluconazole.
Age Restrictions 13 years of age or older
Prescriber Restrictions -
Coverage Duration Oropharyngeal candidiasis: 1 month. All other indications: 6 months
Other Criteria -
Prior Authorization Group NUBEQA
Drug Names NUBEQA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The requested drug will be used in combination with a gonadotropin-releasing hormone
(GnRH) analog or after bilateral orchiectomy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group NUEDEXTA
Drug Names NUEDEXTA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 78
Prior Authorization Group NUPLAZID
Drug Names NUPLAZID
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For hallucinations and delusions associated with Parkinson's disease psychosis, the
diagnosis of Parkinson's disease must be made prior to the onset of psychotic
symptoms.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group OCTREOTIDE
Drug Names OCTREOTIDE ACETATE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Tumor control of thymomas and thymic carcinomas.
Exclusion Criteria -
Required Medical Information For acromegaly (initial): 1) patient has a high pretreatment insulin-like growth factor-1
(IGF-1) level for age and/or gender based on the laboratory reference range, and 2)
patient had an inadequate or partial response to surgery or radiotherapy OR there is a
clinical reason for why the patient has not had surgery or radiotherapy. For acromegaly
(continuation of therapy): patient's IGF-1 level has decreased or normalized since
initiation of therapy. For tumor control of thymomas and thymic carcinomas, the
requested drug will be used as second-line systemic therapy in patients with
unresectable or extrathoracic metastatic disease.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ODOMZO
Drug Names ODOMZO
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 79
Prior Authorization Group OFEV
Drug Names OFEV
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group OGIVRI
Drug Names OGIVRI
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, recurrent or advanced unresectable HER2-positive breast cancer,
leptomeningeal metastases from HER2-positive breast cancer, HER2-positive
esophageal and esophagogastric junction cancer, HER2-positive advanced or
recurrent uterine serous carcinoma, HER2-amplified colorectal cancer in combination
with pertuzumab or lapatinib.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Neoadjuvant therapy for breast cancer: 6 months. Other: Plan Year.
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual. The
patient had an intolerable adverse event to Trazimera and that adverse event was NOT
attributed to the active ingredient as described in the prescribing information.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 80
Prior Authorization Group OMNIPOD
Drug Names OMNIPOD 5 PACK, OMNIPOD DASH 5 PACK, OMNIPOD STARTER KIT
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The patient has diabetes requiring insulin management with multiple daily injections
AND 2) The patient is self-testing glucose levels 4 or more times per day OR the
patient is using a continuous glucose monitor AND 3) The patient has experienced any
of the following with the current diabetes regimen: inadequate glycemic control,
recurrent hypoglycemia, wide fluctuations in blood glucose, dawn phenomenon with
persistent severe early morning hyperglycemia, severe glycemic excursions.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria For continuation of therapy with an insulin pump, the patient has stable or improved
glycemic control.
Prior Authorization Group ONTRUZANT
Drug Names ONTRUZANT
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, recurrent or advanced unresectable HER2-positive breast cancer,
leptomeningeal metastases from HER2-positive breast cancer, HER2-positive
esophageal and esophagogastric junction cancer, HER2-positive advanced or
recurrent uterine serous carcinoma, HER2-amplified colorectal cancer in combination
with pertuzumab or lapatinib.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Neoadjuvant therapy for breast cancer: 6 months. Other: Plan Year.
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual. The
patient had an intolerable adverse event to Trazimera and that adverse event was NOT
attributed to the active ingredient as described in the prescribing information.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 81
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
ONUREG
ONUREG
All FDA-approved Indications
-
Exclusion Criteria -
Required Medical Information
Age Restrictions
Prescriber Restrictions
-
-
-
Coverage Duration
Other Criteria
Plan Year
-
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
OPSUMIT
OPSUMIT
All FDA-approved Indications
-
Exclusion Criteria -
Required Medical Information For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group
1): Diagnosis was confirmed by right heart catheterization. For PAH new starts only: 1)
Pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, 2)
Pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg,
and 3) Pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood
units.
Age Restrictions
Prescriber Restrictions
-
-
Coverage Duration
Other Criteria
Plan Year
-
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 82
Prior Authorization Group ORAL-INTRANASAL FENTANYL
Drug Names FENTANYL CITRATE ORAL TRA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The requested drug is indicated for the treatment of breakthrough CANCER-related
pain only. The requested drug is being prescribed for the management of breakthrough
pain in a CANCER patient with underlying CANCER pain AND 2) The International
Classification of Diseases (ICD) diagnosis code provided supports the CANCER-
RELATED diagnosis. [Note: For drug coverage approval, ICD diagnosis code provided
MUST support the CANCER-RELATED diagnosis.] AND 3) The patient is currently
receiving, and will continue to receive, around-the-clock opioid therapy for underlying
CANCER pain AND 4) The requested drug is intended only for use in opioid tolerant
patients. The patient can safely take the requested dose based on their current opioid
use history. [Note: Patients considered opioid tolerant are those who are taking around-
the-clock medicine consisting of at least 60 mg of oral morphine per day, at least 25
mcg per hour of transdermal fentanyl, at least 30 mg of oral oxycodone per day, at
least 60 mg of oral hydrocodone per day, at least 8 mg of oral hydromorphone per day,
at least 25 mg of oral oxymorphone per day, or an equianalgesic dose of another opioid
medication daily for one week or longer.].
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ORGOVYX
Drug Names ORGOVYX
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 83
Prior Authorization Group ORKAMBI
Drug Names ORKAMBI
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For cystic fibrosis (CF): The requested medication will not be used in combination with
other medications containing ivacaftor.
Age Restrictions 2 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group OXANDROLONE
Drug Names OXANDROLONE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Cachexia associated with AIDS (HIV wasting), To enhance growth in patients with
Turners Syndrome
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Turners Syndrome: Plan Year, All other diagnoses: 6 months
Other Criteria Coverage will be denied if request is for an indication excluded from Medicare Part D.
Prior Authorization Group PANRETIN
Drug Names PANRETIN
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Topical treatment of cutaneous lesions in patients with non-AIDS-related Kaposi
sarcoma
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 84
Prior Authorization Group PAXIL SUSP
Drug Names PAXIL
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group PEGASYS
Drug Names PEGASYS
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Myeloproliferative neoplasm (essential thrombocythemia, polycythemia vera,
symptomatic low risk myelofibrosis), systemic mastocytosis, adult T-cell
leukemia/lymphoma, mycosis fungoides/Sezary syndrome, primary cutaneous CD30+
T-cell lymphoproliferative disorders.
Exclusion Criteria -
Required Medical Information For chronic hepatitis C: Hepatitis C virus (HCV) confirmed by presence of hepatitis C
virus HCV RNA in serum prior to starting treatment and the planned treatment regimen.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration HCV: 12-48 weeks depending on regimen. HBV: 48 weeks. All Other: Plan Year.
Other Criteria -
Prior Authorization Group PEMAZYRE
Drug Names PEMAZYRE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 85
Prior Authorization Group PHENYLBUTYRATE
Drug Names SODIUM PHENYLBUTYRATE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For urea cycle disorder: Diagnosis of urea cycle disorder (UCD) was confirmed by
enzymatic, biochemical or genetic testing.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group PHESGO
Drug Names PHESGO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Neoadjuvant therapy for breast cancer: 6 months. Other: Plan Year
Other Criteria -
Prior Authorization Group PHYTONADIONE TABLETS
Drug Names PHYTONADIONE
PA Indication Indicator -
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration -
Other Criteria PA Indication Indicator: All FDA-approved Indications.
Off-Label Uses: None
Exclusion Criteria : None
Required Medical Information: None
Age Restrictions : None
Prescriber Restrictions : None
Coverage Duration: Plan Year
Other Criteria : None
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 86
Prior Authorization Group PIQRAY
Drug Names PIQRAY 200MG DAILY DOSE, PIQRAY 250MG DAILY DOSE, PIQRAY 300MG
DAILY DOSE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent hormone receptor (HR)-positive, human epidermal growth factor receptor 2
(HER2)-negative, PIK3CA-mutated breast cancer in combination with fulvestrant.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group POMALYST
Drug Names POMALYST
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Systemic light chain amyloidosis, primary central nervous system (CNS) lymphoma,
POEMS syndrome.
Exclusion Criteria -
Required Medical Information For multiple myeloma: The patient has previously received at least two prior therapies
for multiple myeloma, including an immunomodulatory agent AND a proteasome
inhibitor. For Kaposi sarcoma, patient meets one of the following: 1) patient has
acquired immunodeficiency syndrome (AIDS), or 2) patient is negative for human
immunodeficiency virus (HIV).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group POSACONAZOLE
Drug Names POSACONAZOLE DR
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The requested drug will be used orally.
Age Restrictions Treatment of Invasive Aspergillosis: 13 years of age or older, Prophylaxis of Invasive
Aspergillus and Candida Infections: 2 years of age or older
Prescriber Restrictions -
Coverage Duration 6 months
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 87
Prior Authorization Group PRALUENT
Drug Names PRALUENT
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group PREGABALIN
Drug Names PREGABALIN
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Cancer-Related Neuropathic Pain, Cancer Treatment-Related Neuropathic Pain
Exclusion Criteria -
Required Medical Information 1) The requested drug is being prescribed for the management of postherpetic
neuralgia, the management of neuropathic pain associated with diabetic peripheral
neuropathy, cancer-related neuropathic pain, or cancer treatment-related neuropathic
pain AND 2) The patient has experienced an inadequate treatment response,
intolerance, or contraindication to gabapentin OR 3) The requested drug is being
prescribed as adjunctive therapy for the treatment of partial onset seizures OR 4) The
requested drug is being prescribed for the management of fibromyalgia or the
management of neuropathic pain associated with spinal cord injury.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group PREVYMIS
Drug Names PREVYMIS
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For prophylaxis of cytomegalovirus (CMV) infection and disease: 1) The patient is
CMV-seropositive, 2) the patient is a recipient of an allogeneic hematopoietic stem cell
transplant (HSCT), AND 3) The requested medication will not be used beyond Day 100
post-transplantation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 6 months
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 88
Prior Authorization Group PROCRIT
Drug Names PROCRIT
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Anemia due to myelodysplastic syndromes (MDS), anemia in congestive heart failure
(CHF), anemia in rheumatoid arthritis (RA), anemia due to hepatitis C treatment
(ribavirin in combination with either interferon alfa or peginterferon alfa)
Exclusion Criteria Patients receiving chemotherapy with curative intent. Patients with myeloid cancer.
Required Medical Information Requirements regarding hemoglobin (Hgb) values exclude values due to a recent
transfusion. For initial approval: 1) for all uses except anemia due to chemotherapy or
myelodysplastic syndrome (MDS): patient has adequate iron stores (defined as a
transferrin saturation [TSAT] greater than or equal to 20%) AND 2) for all uses except
surgery: pretreatment (no erythropoietin treatment in previous month) Hgb is less than
10 g/dL (less than 9 g/dL for anemia in congestive heart failure), AND 3) for MDS:
pretreatment serum erythropoietin level is 500 international units/L or less. For
reauthorizations (patient received erythropoietin treatment in previous month) in all
uses except surgery: 1) patient has received at least 12 weeks of erythropoietin
therapy, AND 2) patient responded to erythropoietin therapy, AND 3) current Hgb is
less than 12 g/dL, AND 4) for all uses except anemia due to chemotherapy or MDS:
patient has adequate iron stores (defined as a TSAT greater than or equal to 20%).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 16 weeks
Other Criteria Coverage includes use in anemia in patients whose religious beliefs forbid blood
transfusions. Coverage under Part D will be denied if coverage is available under Part
A or Part B as the medication is prescribed and dispensed or administered for the
individual (e.g., used for treatment of anemia for a patient with chronic renal failure who
is undergoing dialysis, or furnished from physician's supply incident to a physician
service).
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 89
Prior Authorization Group PROMACTA
Drug Names PROMACTA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For chronic or persistent immune thrombocytopenia (ITP): 1) For new starts: a) Patient
has had an inadequate response or is intolerant to a prior therapy such as
corticosteroids or immunoglobulins, b) Untransfused platelet (plt) count at any point
prior to the initiation of the requested medication is less than 30,000/mcL OR 30,000-
50,000/mcL with symptomatic bleeding or risk factor(s) for bleeding (e.g., undergoing a
medical or dental procedure where blood loss is anticipated, comorbidities such as
peptic ulcer disease and hypertension, anticoagulation therapy, profession or lifestyle
that predisposes patient to trauma) AND c) For chronic ITP only: patient has had an
inadequate response or intolerance to avatrombopag. 2) For continuation of therapy, plt
count response to the requested drug: a) Current plt count is less than or equal to
200,000/mcL OR b) Current plt count is greater than 200,000/mcL to less than or equal
to 400,000/mcL and dosing will be adjusted to a plt count sufficient to avoid clinically
important bleeding. For thrombocytopenia associated with chronic hepatitis C: 1) For
new starts: the requested drug is used for initiation and maintenance of interferon-
based therapy. 2) For continuation of therapy: patient is receiving interferon-based
therapy. For severe aplastic anemia (AA): For continuation of therapy following the
initial 6 month approval for severe aplastic anemia: The patient must meet one of the
following: 1) Current plt count is 50,000-200,000/mcL OR 2) Current plt count is less
than 50,000/mcL and patient has not received appropriately titrated therapy for at least
16 weeks, OR 3) Current plt count is less than 50,000/mcL and patient is transfusion-
independent, OR 4) Current plt count is greater than 200,000/mcL to less than or equal
to 400,000/mcL and dosing will be adjusted to achieve and maintain an appropriate
target plt count.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration HCV: 6mo, ITP/AA initial: 6mo, ITP reauth: Plan Year, AA reauth: APR-Plan Year, IPR-
16 wks
Other Criteria APR: adequate platelet response (greater than 50,000/mcL), IPR: inadequate platelet
response (less than 50,000/mcL).
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 90
Prior Authorization Group PULMOZYME
Drug Names PULMOZYME
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For cystic fibrosis: Diagnosis of cystic fibrosis was confirmed by appropriate diagnostic
or genetic testing.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
Prior Authorization Group QINLOCK
Drug Names QINLOCK
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 91
Prior Authorization Group QUETIAPINE XR
Drug Names QUETIAPINE FUMARATE ER
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Maintenance monotherapy treatment in bipolar I disorder, monotherapy treatment of
generalized anxiety disorder, monotherapy treatment of major depressive disorder
Exclusion Criteria -
Required Medical Information For schizophrenia, acute treatment of manic or mixed episodes associated with bipolar
I disorder, both as monotherapy and as an adjunct to lithium or divalproex, the acute
treatment of depressive episodes associated with bipolar disorder, maintenance
treatment of bipolar I disorder, as an adjunct to lithium or divalproex, adjunctive
treatment of major depressive disorder, or maintenance monotherapy treatment in
bipolar I disorder: The patient experienced an inadequate treatment response,
intolerance, or contraindication to one of the following generic products: A) aripiprazole,
B) asenapine, C) olanzapine, D) quetiapine immediate-release, E) risperidone, F)
ziprasidone. For all indications: If the patient is 65 years of age or older AND is using
two or more additional central nervous system (CNS) active medications (e.g.,
lorazepam, sertraline, clonazepam, escitalopram, alprazolam, zolpidem) with the
requested drug, the prescriber determined that taking multiple central nervous system
(CNS) active medications is medically necessary. [Note: Use of multiple central
nervous system (CNS) active medications in older adults is associated with an
increased risk of falls.].
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group QUININE SULFATE
Drug Names QUININE SULFATE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Babesiosis, uncomplicated Plasmodium vivax malaria
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 1 month
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 92
Prior Authorization Group REGRANEX
Drug Names REGRANEX
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For the treatment of lower extremity diabetic neuropathic ulcers that extend into the
subcutaneous tissue or beyond and have an adequate blood supply.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 20 weeks
Other Criteria -
Prior Authorization Group RELISTOR INJ
Drug Names RELISTOR
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The requested drug is being prescribed for opioid-induced constipation in an adult
patient with advanced illness or pain caused by active cancer who requires opioid
dosage escalation for palliative care OR 2) The requested drug is being prescribed for
opioid-induced constipation in an adult patient with chronic non-cancer pain, including
chronic pain related to prior cancer or its treatment who does not require frequent (e.g.,
weekly) opioid dosage escalation AND 3) The patient is unable to tolerate oral
medications OR 4) An oral drug indicated for opioid-induced constipation in an adult
patient with chronic non-cancer pain (e.g., Movantik) has been tried AND 5) The patient
experienced an inadequate treatment response or intolerance to an oral drug indicated
for opioid-induced constipation in an adult patient with chronic non-cancer pain (e.g.,
Movantik) OR 6) The patient has a contraindication that would prohibit a trial of an oral
drug indicated for opioid-induced constipation in an adult patient with chronic non-
cancer pain (e.g., Movantik).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 4 months
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 93
Prior Authorization Group REMICADE
Drug Names REMICADE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Behcet's syndrome, granulomatosis with polyangiitis (Wegener's granulomatosis),
hidradenitis suppurativa, juvenile idiopathic arthritis, pyoderma gangrenosum,
sarcoidosis, Takayasu's arteritis, uveitis
Exclusion Criteria -
Required Medical Information For moderately to severely active Crohn's disease (new starts only): 1) Pt has fistulizing
disease, OR 2) Inadequate response to at least one conventional therapy (e.g.,
corticosteroids), OR 3) Intolerance or contraindication (CI) to conventional therapy. For
moderately to severely active ulcerative colitis (new starts only): 1) Inadequate
response to at least one conventional therapy (e.g., corticosteroids) OR 2) Intolerance
or CI to conventional therapy. For moderately to severely active rheumatoid arthritis
(new starts only): 1) Pt meets ANY of the following: a) requested drug will be used in
combination with methotrexate (MTX) or leflunomide OR b) intolerance or CI to MTX
AND leflunomide AND 2) pt meets ANY of the following: a) inadequate response,
intolerance or CI to MTX OR b) inadequate response or intolerance to a prior biologic
disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For
active ankylosing spondylitis (new starts only): Inadequate response to a non-steroidal
anti-inflammatory drug (NSAID) trial OR intolerance or CI to NSAIDs. For moderate to
severe plaque psoriasis (new starts only): 1) At least 3% of body surface area (BSA) is
affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous
areas) are affected at time of diagnosis, AND 2) Pt meets ANY of the following: a) pt
has experienced inadequate response or intolerance to either phototherapy (e.g., UVB,
PUVA) or pharmacologic treatment with MTX, cyclosporine, or acitretin, OR b)
pharmacologic treatment with MTX, cyclosporine, or acitretin is contraindicated, OR c)
pt has severe psoriasis that warrants a biologic DMARD as first-line therapy (i.e. at
least 10% of BSA or crucial body areas [e.g., hands, feet, face, neck, scalp,
genitals/groin, intertriginous areas] are affected).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria For hidradenitis suppurativa (new starts only): pt has severe, refractory disease. For
uveitis (new starts only): Inadequate response or intolerance or has a CI to a trial of
immunosuppressive therapy for uveitis. For FDA-approved indications and off-label
uses that overlap: the patient had an intolerable adverse event to Renflexis and that
adverse event was NOT attributed to the active ingredient as described in the
prescribing information.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 94
Prior Authorization Group RENFLEXIS
Drug Names RENFLEXIS
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Behcet's syndrome, granulomatosis with polyangiitis (Wegener's granulomatosis),
hidradenitis suppurativa, juvenile idiopathic arthritis, pyoderma gangrenosum,
sarcoidosis, Takayasu's arteritis, uveitis
Exclusion Criteria -
Required Medical Information For moderately to severely active Crohn's disease (new starts only): 1) Pt has fistulizing
disease, OR 2) Inadequate response to at least one conventional therapy (e.g.,
corticosteroids), OR 3) Intolerance or contraindication (CI) to conventional therapy. For
moderately to severely active ulcerative colitis (new starts only): 1) Inadequate
response to at least one conventional therapy (e.g., corticosteroids) OR 2) Intolerance
or CI to conventional therapy. For moderately to severely active rheumatoid arthritis
(new starts only): 1) Pt meets ANY of the following: a) requested drug will be used in
combination with methotrexate (MTX) or leflunomide OR b) intolerance or CI to MTX
AND leflunomide AND 2) pt meets ANY of the following: a) inadequate response,
intolerance or CI to MTX OR b) inadequate response or intolerance to a prior biologic
disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For
active ankylosing spondylitis (new starts only): Inadequate response to a non-steroidal
anti-inflammatory drug (NSAID) trial OR intolerance or CI to NSAIDs. For moderate to
severe plaque psoriasis (new starts only): 1) At least 3% of body surface area (BSA) is
affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous
areas) are affected at time of diagnosis, AND 2) Pt meets ANY of the following: a) pt
has experienced inadequate response or intolerance to either phototherapy (e.g., UVB,
PUVA) or pharmacologic treatment with MTX, cyclosporine, or acitretin, OR b)
pharmacologic treatment with MTX, cyclosporine, or acitretin is contraindicated, OR c)
pt has severe psoriasis that warrants a biologic DMARD as first-line therapy (i.e. at
least 10% of BSA or crucial body areas [e.g., hands, feet, face, neck, scalp,
genitals/groin, intertriginous areas] are affected).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria For hidradenitis suppurativa (new starts only): pt has severe, refractory disease. For
uveitis (new starts only): Inadequate response or intolerance or has a CI to a trial of
immunosuppressive therapy for uveitis.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 95
Prior Authorization Group RETEVMO
Drug Names RETEVMO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent or advanced rearranged during transfection (RET)-rearrangement positive
non-small cell lung cancer
Exclusion Criteria -
Required Medical Information For non-small cell lung cancer, patient must meet all of the following: 1) The disease is
recurrent, advanced or metastatic, and 2) Tumor is RET fusion-positive or RET
rearrangement-positive.
Age Restrictions Non-small cell lung cancer: 18 years of age or older. Medullary thyroid cancer and
thyroid cancer: 12 years of age or older.
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group REVLIMID
Drug Names REVLIMID
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Systemic light chain amyloidosis, classical Hodgkin lymphoma, myelodysplastic
syndrome without the 5q deletion cytogenetic abnormality, myelofibrosis-associated
anemia, POEMS syndrome, myeloproliferative neoplasms, non-Hodgkin's lymphoma
with the following subtypes: acquired immunodeficiency syndrome (AIDS)-related non-
germinal center diffuse large B-cell lymphoma, primary central nervous system (CNS)
lymphoma, monomorphic post-transplant lymphoproliferative disorder, chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell
lymphoma, multicentric Castleman's disease, adult T-cell leukemia/lymphoma, mycosis
fungoides (MF)/Sezary syndrome (SS), angioimmunoblastic T-cell lymphoma (AITL),
peripheral T-cell lymphoma not otherwise specified (PTCL NOS), enteropathy-
associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma,
nodal peripheral T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma
(ALCL), hepatosplenic T-cell lymphoma, high-grade B-cell lymphomas, histologic
transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma,
histologic transformation of follicular lymphoma to diffuse large B-cell lymphoma, AIDS-
related Kaposi sarcoma, smoldering myeloma
Exclusion Criteria -
Required Medical Information For myelodysplastic syndrome (MDS): Lower risk MDS with symptomatic anemia per
the Revised International Prognostic Scoring System (IPSS-R), International Prognostic
Scoring System (IPSS), or World Health organization (WHO) classification-based
Prognostic Scoring System (WPSS).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group REZUROCK
Drug Names REZUROCK
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions 12 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 96
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
RIABNI
RIABNI
All FDA-approved Indications, Some Medically-accepted Indications
Non-Hodgkin's lymphoma subtypes [small lymphocytic lymphoma (SLL), mantle cell
lymphoma, marginal zone lymphomas (nodal, splenic, gastric mucosa-associated
lymphoid tissue [MALT], nongastric MALT), Burkitt lymphoma, primary cutaneous B-cell
lymphoma, high-grade B-cell lymphoma with translocations of MYC and BCL2 and/or
BCL6 (double/triple hit lymphoma), high-grade B-cell lymphoma not otherwise
specified, histological transformation from follicular lymphoma to diffuse large B-cell
lymphoma, histological transformation from nodal marginal zone lymphoma to diffuse
large B-cell lymphoma, Castleman's disease, acquired immunodeficiency syndrome
(AIDS)-related B-cell lymphoma, hairy cell leukemia, post-transplant lymphoproliferative
disorder (PTLD), B-cell lymphoblastic lymphoma], refractory immune or idiopathic
thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, Waldenstrom's
macroglobulinemia/lymphoplasmacytic lymphoma, chronic graft-versus-host disease
(GVHD), Sjogren syndrome, thrombotic thrombocytopenic purpura, refractory
myasthenia gravis, Hodgkin's lymphoma (nodular lymphocyte-predominant), primary
central nervous system (CNS) lymphoma, leptomeningeal metastases from
lymphomas, acute lymphoblastic leukemia, prevention of Epstein-Barr virus (EBV)-
related PTLD, multiple sclerosis, immune checkpoint inhibitor-related toxicities,
moderately to severely active rheumatoid arthritis, and pemphigus vulgaris
-
For moderately to severely active rheumatoid arthritis (new starts only): 1) patient
meets ANY of the following: a) requested drug will be used in combination with
methotrexate (MTX) OR b) patient has intolerance or contraindication to MTX, AND 2)
patient meets ANY of the following: a) inadequate response, intolerance, or
contraindication to MTX OR b) inadequate response or intolerance to a prior biologic
disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD.
Hematologic malignancies must be CD20-positive. For multiple sclerosis: 1) patient has
a diagnosis of relapsing remitting multiple sclerosis and 2) patient has had an
inadequate response to two or more disease-modifying drugs indicated for multiple
sclerosis despite adequate duration of treatment.
-
-
Immune checkpoint inhibitor-related toxicities: 3 months, All other: Plan Year
The patient had an intolerable adverse event to both Truxima AND Ruxience and that
adverse event was NOT attributed to the active ingredient as described in the
prescribing information.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 97
Prior Authorization Group RINVOQ
Drug Names RINVOQ
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For moderately to severely active rheumatoid arthritis (new starts only): 1) inadequate
response, intolerance or contraindication to methotrexate (MTX) OR 2) inadequate
response or intolerance to a prior biologic disease-modifying antirheumatic drug
(DMARD) or a targeted synthetic DMARD.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 98
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
RITUXAN
RITUXAN
All FDA-approved Indications, Some Medically-accepted Indications
Non-Hodgkin's lymphoma subtypes [small lymphocytic lymphoma (SLL), mantle cell
lymphoma, marginal zone lymphomas (nodal, splenic, gastric mucosa-associated
lymphoid tissue [MALT], nongastric MALT), Burkitt lymphoma, primary cutaneous B-cell
lymphoma, high-grade B-cell lymphoma with translocations of MYC and BCL2 and/or
BCL6 (double/triple hit lymphoma), high-grade B-cell lymphoma not otherwise
specified, histological transformation from follicular lymphoma to diffuse large B-cell
lymphoma, histological transformation from nodal marginal zone lymphoma to diffuse
large B-cell lymphoma, Castleman's disease, acquired immunodeficiency syndrome
(AIDS)-related B-cell lymphoma, hairy cell leukemia, post-transplant lymphoproliferative
disorder (PTLD), B-cell lymphoblastic lymphoma], refractory immune or idiopathic
thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, Waldenstrom's
macroglobulinemia/lymphoplasmacytic lymphoma, chronic graft-versus-host disease
(GVHD), Sjogren syndrome, thrombotic thrombocytopenic purpura, refractory
myasthenia gravis, Hodgkin's lymphoma (nodular lymphocyte-predominant), primary
central nervous system (CNS) lymphoma, leptomeningeal metastases from
lymphomas, acute lymphoblastic leukemia, prevention of Epstein-Barr virus (EBV)-
related PTLD, multiple sclerosis, and immune checkpoint inhibitor-related toxicities
-
For moderately to severely active rheumatoid arthritis (new starts only): 1) patient
meets ANY of the following: a) requested drug will be used in combination with
methotrexate (MTX) OR b) patient has intolerance or contraindication to MTX, AND 2)
patient meets ANY of the following: a) inadequate response, intolerance, or
contraindication to MTX OR b) inadequate response or intolerance to a prior biologic
disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD.
Hematologic malignancies must be CD20-positive. For multiple sclerosis: 1) patient has
a diagnosis of relapsing remitting multiple sclerosis and 2) patient has had an
inadequate response to two or more disease-modifying drugs indicated for multiple
sclerosis despite adequate duration of treatment.
-
-
Immune checkpoint inhibitor-related toxicities: 3 months, All other: Plan Year
The patient had an intolerable adverse event to both Truxima AND Ruxience and that
adverse event was NOT attributed to the active ingredient as described in the
prescribing information.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 99
Prior Authorization Group RITUXAN HYCELA
Drug Names RITUXAN HYCELA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Castleman's disease (CD), high-grade B-cell lymphoma, histologic transformation of
nodal marginal zone lymphoma to diffuse large B-cell lymphoma, marginal zone
lymphomas (nodal marginal zone lymphoma, gastric mucosa-associated lymphoid
tissue (MALT) lymphoma, nongastric MALT lymphoma, and splenic marginal zone
lymphoma), mantle cell lymphoma, post-transplant lymphoproliferative disorder (PTLD),
primary cutaneous B-cell lymphoma (e.g., cutaneous marginal zone lymphoma or
cutaneous follicle center lymphomas), hairy cell leukemia, small lymphocytic lymphoma
(SLL).
Exclusion Criteria -
Required Medical Information Malignancies must be CD20 positive. Patient must receive at least one full dose of a
rituximab product by intravenous infusion without experiencing severe adverse
reactions.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ROZLYTREK
Drug Names ROZLYTREK
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent or advanced ROS1-positive non-small cell lung cancer (NSCLC), advanced,
recurrent, or persistent neurotrophic tyrosine receptor kinase (NTRK) gene fusion-
positive solid tumors, first-line treatment of NTRK gene fusion-positive solid tumors.
Exclusion Criteria -
Required Medical Information For all neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors,
the disease is without a known acquired resistance mutation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 100
Prior Authorization Group RUBRACA
Drug Names RUBRACA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For metastatic castration-resistant prostate cancer with a deleterious breast cancer
susceptibility gene (BRCA) mutation (germline and/or somatic): 1) patient has been
treated with androgen receptor-directed therapy, 2) patient has been treated with a
taxane-based chemotherapy or the patient is not fit for chemotherapy, 3) the requested
drug will be used in combination with a gonadotropin-releasing hormone (GnRH)
analog or after bilateral orchiectomy, and 4) patient experienced an unacceptable
toxicity with a trial of Lynparza (olaparib). For maintenance treatment of patients with
recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a
complete or partial response to platinum-based chemotherapy, patient experienced an
unacceptable toxicity with a trial of Lynparza (olaparib). For treatment of patients with a
deleterious breast cancer susceptibility gene (BRCA) mutation (germline and/or
somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who
have been treated with two or more chemotherapies: if prescribed for deleterious
germline BRCA-mutated advanced ovarian cancer treated with two or more prior
chemotherapies, the patient experienced an unacceptable toxicity with a trial of
Lynparza (olaparib).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 101
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
RUXIENCE
RUXIENCE
All FDA-approved Indications, Some Medically-accepted Indications
Non-Hodgkin's lymphoma subtypes [small lymphocytic lymphoma (SLL), mantle cell
lymphoma, marginal zone lymphomas (nodal, splenic, gastric mucosa-associated
lymphoid tissue [MALT], nongastric MALT), Burkitt lymphoma, primary cutaneous B-cell
lymphoma, high-grade B-cell lymphoma with translocations of MYC and BCL2 and/or
BCL6 (double/triple hit lymphoma), high-grade B-cell lymphoma not otherwise
specified, histological transformation from follicular lymphoma to diffuse large B-cell
lymphoma, histological transformation from nodal marginal zone lymphoma to diffuse
large B-cell lymphoma, Castleman's disease, acquired immunodeficiency syndrome
(AIDS)-related B-cell lymphoma, hairy cell leukemia, post-transplant lymphoproliferative
disorder (PTLD), B-cell lymphoblastic lymphoma], refractory immune or idiopathic
thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, Waldenstrom's
macroglobulinemia/lymphoplasmacytic lymphoma, chronic graft-versus-host disease
(GVHD), Sjogren syndrome, thrombotic thrombocytopenic purpura, refractory
myasthenia gravis, Hodgkin's lymphoma (nodular lymphocyte-predominant), primary
central nervous system (CNS) lymphoma, leptomeningeal metastases from
lymphomas, acute lymphoblastic leukemia, prevention of Epstein-Barr virus (EBV)-
related PTLD, multiple sclerosis, immune checkpoint inhibitor-related toxicities,
pemphigus vulgaris, and moderately to severely active rheumatoid arthritis
-
For moderately to severely active rheumatoid arthritis (new starts only): 1) patient
meets ANY of the following: a) requested drug will be used in combination with
methotrexate (MTX) OR b) patient has intolerance or contraindication to MTX, AND 2)
patient meets ANY of the following: a) inadequate response, intolerance, or
contraindication to MTX OR b) inadequate response or intolerance to a prior biologic
disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD.
Hematologic malignancies must be CD20-positive. For multiple sclerosis: 1) patient has
a diagnosis of relapsing remitting multiple sclerosis and 2) patient has had an
inadequate response to two or more disease-modifying drugs indicated for multiple
sclerosis despite adequate duration of treatment.
-
-
Immune checkpoint inhibitor-related toxicities: 3 months, All other: Plan Year
-
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 102
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
RYDAPT
RYDAPT
All FDA-approved Indications, Some Medically-accepted Indications
Relapsed or refractory acute myeloid leukemia (AML), myeloid, lymphoid, or mixed
lineage neoplasms with eosinophilia and FGFR1 or FLT3 rearrangements, post-
remission maintenance therapy for acute myeloid leukemia (AML), re-induction in
residual disease for acute myeloid leukemia (AML)
-
For acute myeloid leukemia (AML): AML must be FLT3 mutation-positive. For myeloid,
lymphoid, or mixed lineage neoplasms with eosinophilia and FGFR1 or FLT3
rearrangements: the disease is in chronic or blast phase.
-
-
Plan Year
-
SAPROPTERIN
SAPROPTERIN DIHYDROCHLORI
All FDA-approved Indications
-
-
For phenylketonuria: For patients who have not yet received a therapeutic trial of the
requested drug, the patient's pretreatment, including before dietary management,
phenylalanine level is greater than 6 mg/dL (360 micromol/L). For patients who
completed a therapeutic trial of the requested drug, the patient must have experienced
improvement (for example, reduction in blood phenylalanine levels, improvement in
neuropsychiatric symptoms).
-
-
Initial: 2 months. All others: Plan Year.
-
SIGNIFOR
SIGNIFOR
All FDA-approved Indications
-
-
-
-
Endocrinologist
Plan Year
-
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 103
Prior Authorization Group SILDENAFIL
Drug Names SILDENAFIL CITRATE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group
1): Diagnosis was confirmed by right heart catheterization. For PAH new starts only: 1)
Pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, 2)
Pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg,
and 3) Pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood
units.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group SIRTURO
Drug Names SIRTURO
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions Prescribed by or in consultation with an infectious disease specialist.
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 104
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
SKYRIZI
SKYRIZI, SKYRIZI PEN
All FDA-approved Indications
-
-
For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body
surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck,
groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets
any of the following: a) patient has experienced an inadequate response or intolerance
to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with
methotrexate, cyclosporine, or acitretin, or b) pharmacologic treatment with
methotrexate, cyclosporine, or acitretin is contraindicated, or c) patient has severe
psoriasis that warrants a biologic disease-modifying antirheumatic drug (DMARD) as
first-line therapy (i.e. at least 10% of the body surface area or crucial body areas [e.g.,
hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected).
-
-
Plan Year
-
SOMATULINE DEPOT
SOMATULINE DEPOT
All FDA-approved Indications, Some Medically-accepted Indications
Tumor control of neuroendocrine tumors (NETs) of the lung, thymus (carcinoid tumors)
or unresected primary gastrinoma, and pheochromocytoma/paraganglioma.
-
For acromegaly (initial): 1) patient has a high pretreatment insulin-like growth factor-1
(IGF-1) level for age and/or gender based on the laboratory reference range, and 2)
patient had an inadequate or partial response to surgery or radiotherapy OR there is a
clinical reason for why the patient has not had surgery or radiotherapy. For acromegaly
continuation of therapy: patient's IGF-1 level has decreased or normalized since
initiation of therapy. For tumor control, the requested drug will be used for any of the
following: 1) neuroendocrine tumor of the thymus or lung in patients with locoregional
unresectable disease and/or distant metastatic disease, OR 2) unresected primary
gastrinoma, OR 3) pheochromocytomas and paragangliomas, used for either of the
following: a) symptomatic locally unresectable disease with somatostatin receptor
positive imaging OR b) secreting tumor in metastatic disease.
-
-
Plan Year
-
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 105
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 106
Prior Authorization Group SOMAVERT
Drug Names SOMAVERT
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For acromegaly (initial): 1) patient has a high pretreatment insulin-like growth factor-1
(IGF-1) level for age and/or gender based on the laboratory reference range, and 2)
patient had an inadequate or partial response to surgery or radiotherapy OR there is a
clinical reason for why the patient has not had surgery or radiotherapy. For acromegaly
continuation of therapy: patient's IGF-1 level has decreased or normalized since
initiation of therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group SPRYCEL
Drug Names SPRYCEL
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Gastrointestinal stromal tumor (GIST), metastatic chondrosarcoma, recurrent
chordoma, T-cell acute lymphoblastic leukemia (ALL), Philadelphia (Ph)-like B-ALL
Exclusion Criteria -
Required Medical Information For chronic myeloid leukemia (CML), including patients who have received a
hematopoietic stem cell transplant: diagnosis was confirmed by detection of the
Philadelphia (Ph) chromosome or BCR-ABL gene. If patient experienced resistance to
an alternative tyrosine kinase inhibitor for CML, patient is negative for T315I/A,
F317L/V/I/C, and V299L mutations. For acute lymphoblastic leukemia (ALL), the patient
has a diagnosis of one of the following: 1) Philadelphia chromosome positive ALL that
has been confirmed by detection of the Ph chromosome or BCR-ABL gene, OR 2) Ph-
like B-ALL with ABL-class kinase fusion, OR 3) relapsed or refractory T-cell ALL with
ABL-class translocation. For GIST, patient must have progressed on imatinib, sunitinib,
and regorafenib.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 107
Prior Authorization Group STELARA
Drug Names STELARA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For moderate to severe plaque psoriasis (new starts only): 1) At least 3% of body
surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck,
groin, intertriginous areas) are affected at the time of diagnosis and 2) Patient had an
inadequate response, intolerance, or contraindication to two of the following products:
Enbrel (etanercept), Humira (adalimumab), Skyrizi (risankizumab-rzaa). For active
psoriatic arthritis (PsA) (new starts): patient had an inadequate response, intolerance,
or contraindication to two of the following products: Enbrel (etanercept), Humira
(adalimumab), Xeljanz (tofacitinib)/Xeljanz XR (tofacitinib extended-release). For
moderately to severely active Crohn's disease (new starts): patient had an inadequate
response, intolerance, or contraindication to Humira (adalimumab). For moderately to
severely active ulcerative colitis (new starts): patient had an inadequate response,
intolerance, or contraindication to both Humira (adalimumab) and Xeljanz
(tofacitinib)/Xeljanz XR (tofacitinib extended-release).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group STIVARGA
Drug Names STIVARGA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Progressive gastrointestinal stromal tumors (GIST), osteosarcoma, glioblastoma,
angiosarcoma, retroperitoneal/intra-abdominal soft tissue sarcoma,
rhabdomyosarcoma, solitary fibrous tumor, and soft tissue sarcomas of the extremities,
body wall, head and neck, advanced colorectal cancer.
Exclusion Criteria -
Required Medical Information For gastrointestinal stromal tumors: The disease is progressive, locally advanced,
unresectable, or metastatic.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 108
Prior Authorization Group SUTENT
Drug Names SUNITINIB MALATE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Thyroid carcinoma (follicular, medullary, papillary, and Hurthle cell), soft tissue sarcoma
(angiosarcoma, solitary fibrous tumor, and alveolar soft part sarcoma subtypes),
recurrent chordoma, thymic carcinoma.
Exclusion Criteria -
Required Medical Information For renal cell carcinoma, the disease is relapsed, advanced, or stage IV.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group SYMDEKO
Drug Names SYMDEKO
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The requested medication will not be used in combination with other medications
containing ivacaftor.
Age Restrictions 6 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group SYMPAZAN
Drug Names SYMPAZAN
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions 2 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 109
Prior Authorization Group SYNRIBO
Drug Names SYNRIBO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Follow-up therapy for chronic myeloid leukemia (CML) patients after hematopoietic
stem cell transplant (HSCT)
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TABRECTA
Drug Names TABRECTA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Treatment of recurrent or advanced non-small cell lung cancer (NSCLC).
Exclusion Criteria -
Required Medical Information For recurrent, advanced, or metastatic NSCLC: Tumor is positive for mesenchymal-
epithelial transition (MET) exon 14 skipping mutation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 110
Prior Authorization Group TAFINLAR
Drug Names TAFINLAR
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Brain metastases from melanoma, thyroid carcinoma (papillary carcinoma, follicular
carcinoma, and Hurthle cell carcinoma), central nervous system (CNS) cancer (i.e.,
glioma, meningioma, astrocytoma)
Exclusion Criteria -
Required Medical Information For brain metastases from melanoma, adjuvant treatment of melanoma, and central
nervous system (CNS) cancer (i.e., glioma, meningioma, astrocytoma): 1) The tumor is
positive for a BRAF V600 activating mutation (e.g., V600E or V600K), and 2) The
requested drug will be used in combination with trametinib. For unresectable or
metastatic melanoma: 1) The tumor is positive for a BRAF V600 activating mutation
(e.g., V600E or V600K), and 2) The requested drug will be used as a single agent or in
combination with trametinib. For non-small cell lung cancer: 1) The tumor is positive for
a BRAF V600E mutation, and 2) The requested drug will be used in combination with
trametinib. For thyroid carcinoma with papillary, follicular, or Hurthle histology: The
tumor is positive for BRAF activating mutation (e.g., V600E or V600K).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TAGRISSO
Drug Names TAGRISSO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Sensitizing epidermal growth factor receptor (EGFR) mutation-positive recurrent or
advanced non-small cell lung cancer (NSCLC), brain metastases from sensitizing
EGFR mutation-positive NSCLC, leptomeningeal metastases from EGFR mutation-
positive NSCLC
Exclusion Criteria -
Required Medical Information For NSCLC, the requested drug is used in any of the following settings: 1) The patient
meets both of the following: a) patient has metastatic, advanced, or recurrent NSCLC
(including brain and/or leptomeningeal metastases from NSCLC) and b) patient has a
sensitizing EGFR mutation OR 2) Patient meets both of the following: a) request is for
adjuvant treatment of NSCLC following tumor resection and b) patient has EGFR
mutation-positive disease.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 111
Prior Authorization Group TALTZ
Drug Names TALTZ
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For moderate to severe plaque psoriasis (new starts only): 1) At least 3% of body
surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck,
groin, intertriginous areas) are affected at the time of diagnosis AND 2) the patient had
an inadequate response, intolerance, or contraindication to one of the following
products: Enbrel (etanercept), Humira (adalimumab), Skyrizi (risankizumab-rzaa). For
active ankylosing spondylitis (new starts only): the patient had an inadequate response,
intolerance, or contraindication to either Enbrel (etanercept) or Humira (adalimumab).
For active psoriatic arthritis (PsA) (new starts only): the patient had an inadequate
response, intolerance, or contraindication to one of the following products: Enbrel
(etanercept), Humira (adalimumab), Xeljanz (tofacitinib)/Xeljanz XR (tofacitinib
extended-release). For active axial spondyloarthritis (new starts only): Patient meets
any of the following: 1) has had an inadequate response to a non-steroidal anti-
inflammatory drug (NSAID) trial or 2) has an intolerance or contraindication to NSAIDs.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TALZENNA
Drug Names TALZENNA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent germline breast cancer susceptibility gene (BRCA)-mutated breast cancer
Exclusion Criteria -
Required Medical Information For germline BRCA-mutated (gBRCAm) metastatic or recurrent breast cancer, the
patient experienced an unacceptable toxicity with a trial of Lynparza (olaparib).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 112
Prior Authorization Group TARGRETIN TOPICAL
Drug Names TARGRETIN
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Mycosis fungoides, chronic or smoldering adult T-cell leukemia/lymphoma, primary
cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TASIGNA
Drug Names TASIGNA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL),
gastrointestinal stromal tumor (GIST)
Off-label Uses
Exclusion Criteria -
Required Medical Information For chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL), diagnosis
was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene. For
CML, including patients newly diagnosed with CML and patients who have received a
hematopoietic stem cell transplant: patient has experienced resistance or intolerance to
imatinib or dasatinib. If patient experienced resistance to an alternative tyrosine kinase
inhibitor for CML, patient is negative for T315I, Y253H, E255K/V, F359V/C/I, and
G250E mutations. For GIST, patient must have progressed on imatinib, sunitinib, and
regorafenib.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 113
Prior Authorization Group TAZAROTENE
Drug Names TAZAROTENE, TAZORAC
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For plaque psoriasis: 1) The requested drug is being prescribed to treat less than 20
percent of the patient's body surface area AND 2) The patient experienced an
inadequate treatment response or intolerance to at least one topical corticosteroid OR
has a contraindication that would prohibit a trial of topical corticosteroids.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TAZVERIK
Drug Names TAZVERIK
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions Epithelioid sarcoma: 16 years of age or older, Follicular lymphoma: 18 years of age or
older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 114
Prior Authorization Group TECENTRIQ
Drug Names TECENTRIQ
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent or advanced non-small cell lung cancer, PD-L1 positive triple negative
recurrent breast cancer in combination with paclitaxel protein-bound
Exclusion Criteria -
Required Medical Information For urothelial carcinoma, patient meets one of the following criteria: 1) Patient is
ineligible for cisplatin therapy and tumors express PD-L1 (defined as PD-L1 stained
tumor-infiltrating immune cells [IC] covering greater than or equal to 5 percent of the
tumor area) OR 2) Patient is ineligible for any platinum containing chemotherapy. For
non-small cell lung cancer (NSCLC), patient has recurrent, advanced or metastatic
disease AND the requested drug will be used as any of the following: 1) first-line
treatment of tumors with high PD-L1 expression (defined as PD-L1 stained greater than
or equal to 50 percent of tumor cells or PD-L1 stained tumor-infiltrating immune cells
[IC] covering greater than or equal to 10 percent of the tumor area) and no EGFR or
ALK genomic tumor aberrations, 2) used in combination with carboplatin, paclitaxel,
and bevacizumab, or in combination with carboplatin and albumin-bound paclitaxel for
nonsquamous NSCLC, or 3) the requested drug will be used as subsequent therapy or
continuation maintenance therapy. For hepatocellular carcinoma, the requested drug
will be used as initial treatment in combination with bevacizumab.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TEMAZEPAM 30MG
Drug Names TEMAZEPAM
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information Prescriber must acknowledge that the benefit of therapy with the requested drug
outweighs the potential risks for the patient. (Note: The American Geriatrics Society
identifies the use of this medication as potentially inappropriate in older adults, meaning
it is best avoided, prescribed at reduced dosage, or used with caution or carefully
monitored.) The patient has experienced an inadequate treatment response,
intolerance, or has a contraindication to doxepin (3 mg or 6 mg).
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria This Prior Authorization requirement only applies to patients 65 years of age or older.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 115
Prior Authorization Group TEPMETKO
Drug Names TEPMETKO
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TESTOSTERONE CYPIONATE INJ
Drug Names TESTOSTERONE CYPIONATE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Gender Dysphoria
Exclusion Criteria -
Required Medical Information Primary or hypogonadotropic hypogonadism: 1) Request is for continuation of
testosterone therapy and the patient had a confirmed low morning testosterone level
according to current practice guidelines or your standard lab reference values before
starting testosterone therapy [Note: Safety and efficacy of testosterone products in
patients with "age-related hypogonadism" (also referred to as "late-onset
hypogonadism") have not been established.] OR 2) Request is not for continuation of
testosterone therapy and the patient has at least two confirmed low morning
testosterone levels according to current practice guidelines or your standard lab
reference values [Note: Safety and efficacy of testosterone products in patients with
"age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not
been established.].
Gender dysphoria: The patient is able to make an informed decision to engage in
hormone therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 116
Prior Authorization Group TESTOSTERONE ENANTHATE INJ
Drug Names TESTOSTERONE ENANTHATE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Gender Dysphoria
Exclusion Criteria -
Required Medical Information Primary or hypogonadotropic hypogonadism: 1) Request is for continuation of
testosterone therapy and the patient had a confirmed low morning testosterone level
according to current practice guidelines or your standard lab reference values before
starting testosterone therapy [Note: Safety and efficacy of testosterone products in
patients with "age-related hypogonadism" (also referred to as "late-onset
hypogonadism") have not been established.] OR 2) Request is not for continuation of
testosterone therapy and the patient has at least two confirmed low morning
testosterone levels according to current practice guidelines or your standard lab
reference values [Note: Safety and efficacy of testosterone products in patients with
"age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not
been established.].
Gender dysphoria: The patient is able to make an informed decision to engage in
hormone therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TETRABENAZINE
Drug Names TETRABENAZINE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Tic disorders, tardive dyskinesia, hemiballismus, chorea not associated with
Huntington's disease.
Exclusion Criteria -
Required Medical Information For treatment of chorea associated with Huntington's disease: The patient must have a
prior inadequate response or intolerable adverse event with deutetrabenazine therapy.
For treatment of tardive dyskinesia: The patient must have a prior inadequate response
or intolerable adverse event with deutetrabenazine or valbenazine therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 117
Prior Authorization Group TETRACYCLINE
Drug Names TETRACYCLINE HYDROCHLORID
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The patient will use the requested drug orally.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group THALOMID
Drug Names THALOMID
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Myelofibrosis-related anemia, recurrent aphthous stomatitis, recurrent human
immunodeficiency virus (HIV)-associated aphthous ulcers, cachexia, HIV-associated
diarrhea, acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma,
Behcet's syndrome, chronic graft-versus-host disease, Crohn's disease, multicentric
Castleman's disease.
Exclusion Criteria -
Required Medical Information For cachexia: Cachexia must be due to cancer or HIV infection.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 118
Prior Authorization Group TIBSOVO
Drug Names TIBSOVO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Conventional (grades 1-3) or dedifferentiated chondrosarcoma
Exclusion Criteria -
Required Medical Information Patient has disease with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. For
acute myeloid leukemia (AML): 1) patient has newly-diagnosed AML and meets one of
the following: a) 75 years of age or older, b) patient has comorbidities that preclude use
of intensive induction chemotherapy, or c) patient is 60 physiologic years of age or
older and declines intensive induction chemotherapy, OR 2) patient is 60 physiologic
years of age or older and the requested drug will be used as post-induction therapy
following response to induction therapy with the requested drug, OR 3) patient has
relapsed or refractory AML. For unresectable or metastatic cholangiocarcinoma: the
requested drug will be used as subsequent treatment for progression on or after
systemic treatment.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TOBRAMYCIN
Drug Names TOBRAMYCIN
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Non-cystic fibrosis bronchiectasis
Exclusion Criteria -
Required Medical Information For cystic fibrosis and non-cystic fibrosis bronchiectasis, the patient must meet one of
the following: 1) Pseudomonas aeruginosa is present in the patient's airway cultures,
OR 2) the patient has a history of Pseudomonas aeruginosa infection or colonization in
the airways.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 119
Prior Authorization Group TOPICAL LIDOCAINE
Drug Names GLYDO, LIDOCAINE, LIDOCAINE HCL, LIDOCAINE HCL JELLY,
LIDOCAINE/PRILOCAINE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The requested drug is being used for topical anesthesia, AND 2) If the requested
drug will be used as part of a compounded product, then all the active ingredients in the
compounded product are Food and Drug Administration (FDA) approved for topical
use.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 3 months
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
Prior Authorization Group TOPICAL TESTOSTERONES
Drug Names ANDRODERM, TESTOSTERONE, TESTOSTERONE PUMP
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Gender Dysphoria
Exclusion Criteria -
Required Medical Information Primary or hypogonadotropic hypogonadism: 1) Request is for continuation of
testosterone therapy and the patient had a confirmed low morning testosterone level
according to current practice guidelines or your standard lab reference values before
starting testosterone therapy [Note: Safety and efficacy of testosterone products in
patients with "age-related hypogonadism" (also referred to as "late-onset
hypogonadism") have not been established.] OR 2) Request is not for continuation of
testosterone therapy and the patient has at least two confirmed low morning
testosterone levels according to current practice guidelines or your standard lab
reference values [Note: Safety and efficacy of testosterone products in patients with
"age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not
been established.].
Gender dysphoria: The patient is able to make an informed decision to engage in
hormone therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 120
Prior Authorization Group TOPICAL TRETINOIN
Drug Names AVITA, TRETINOIN
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TRAZIMERA
Drug Names TRAZIMERA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, recurrent or advanced unresectable HER2-positive breast cancer,
leptomeningeal metastases from HER2-positive breast cancer, HER2-positive
esophageal and esophagogastric junction cancer, HER2-positive advanced or
recurrent uterine serous carcinoma, HER2-amplified colorectal cancer in combination
with pertuzumab or lapatinib.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Neoadjuvant therapy for breast cancer: 6 months. Other: Plan Year.
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
Prior Authorization Group TRELSTAR
Drug Names TRELSTAR MIXJECT
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Gender dysphoria
Exclusion Criteria -
Required Medical Information For gender dysphoria, patient meets either of the following (1 or 2): 1) the requested
drug is used to suppress puberty and the patient is at Tanner stage 2 or greater, OR 2)
patient is undergoing gender transition, and the patient will receive the requested drug
concomitantly with gender-affirming hormones.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
TREPROSTINIL INJ
TREPROSTINIL
All FDA-approved Indications
-
-
For pulmonary arterial hypertension (World Health Organization [WHO] Group 1), the
diagnosis was confirmed by right heart catheterization. For new starts only: 1)
pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, 2)
pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg,
AND 3) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood
units.
-
-
Plan Year
Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
TRIENTINE
TRIENTINE HYDROCHLORIDE
All FDA-approved Indications
-
-
-
-
-
Plan Year
-
TRIKAFTA
TRIKAFTA
All FDA-approved Indications
-
-
The requested medication will not be used in combination with other medications
containing ivacaftor.
6 years of age or older
-
Plan Year
-
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 121
Prior Authorization Group TRUSELTIQ
Drug Names TRUSELTIQ
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 122
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
TRUXIMA
TRUXIMA
All FDA-approved Indications, Some Medically-accepted Indications
Non-Hodgkin's lymphoma subtypes [small lymphocytic lymphoma (SLL), mantle cell
lymphoma, marginal zone lymphomas (nodal, splenic, gastric mucosa-associated
lymphoid tissue [MALT], nongastric MALT), Burkitt lymphoma, primary cutaneous B-cell
lymphoma, high-grade B-cell lymphoma with translocations of MYC and BCL2 and/or
BCL6 (double/triple hit lymphoma), high-grade B-cell lymphoma not otherwise
specified, histological transformation from follicular lymphoma to diffuse large B-cell
lymphoma, histological transformation from nodal marginal zone lymphoma to diffuse
large B-cell lymphoma, Castleman's disease, acquired immunodeficiency syndrome
(AIDS)-related B-cell lymphoma, hairy cell leukemia, post-transplant lymphoproliferative
disorder (PTLD), B-cell lymphoblastic lymphoma], refractory immune or idiopathic
thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, Waldenstrom's
macroglobulinemia/lymphoplasmacytic lymphoma, chronic graft-versus-host disease
(GVHD), Sjogren syndrome, thrombotic thrombocytopenic purpura, refractory
myasthenia gravis, Hodgkin's lymphoma (nodular lymphocyte-predominant), primary
central nervous system (CNS) lymphoma, leptomeningeal metastases from
lymphomas, acute lymphoblastic leukemia, prevention of Epstein-Barr virus (EBV)-
related PTLD, multiple sclerosis, immune checkpoint inhibitor-related toxicities, and
pemphigus vulgaris
-
For moderately to severely active rheumatoid arthritis (new starts only): 1) patient
meets ANY of the following: a) requested drug will be used in combination with
methotrexate (MTX) OR b) patient has intolerance or contraindication to MTX, AND 2)
patient meets ANY of the following: a) inadequate response, intolerance, or
contraindication to MTX OR b) inadequate response or intolerance to a prior biologic
disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD.
Hematologic malignancies must be CD20-positive. For multiple sclerosis: 1) patient has
a diagnosis of relapsing remitting multiple sclerosis and 2) patient has had an
inadequate response to two or more disease-modifying drugs indicated for multiple
sclerosis despite adequate duration of treatment.
-
-
Immune checkpoint inhibitor-related toxicities: 3 months, All other: Plan Year
-
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 123
Prior Authorization Group TUKYSA
Drug Names TUKYSA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer,
including patients with brain metastases, who have received one or more lines of prior
HER2-targeted therapy in the metastatic setting.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group TURALIO
Drug Names TURALIO
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group UBRELVY
Drug Names UBRELVY
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The patient has experienced an inadequate treatment response, intolerance, or the
patient has a contraindication to one triptan 5-HT1 receptor agonist.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 124
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
Prior Authorization Group
Drug Names
PA Indication Indicator
Off-label Uses
Exclusion Criteria
Required Medical Information
Age Restrictions
Prescriber Restrictions
Coverage Duration
Other Criteria
UCERIS
BUDESONIDE ER
All FDA-approved Indications
-
-
The patient has experienced an inadequate treatment response, intolerance, or has a
contraindication to at least one 5-aminosalicylic acid (5-ASA) therapy.
-
-
2 months
-
UKONIQ
UKONIQ
All FDA-approved Indications
-
-
-
-
-
Plan Year
-
V-GO
V-GO 20, V-GO 30, V-GO 40
All FDA-approved Indications
-
-
1) The patient has diabetes requiring insulin management with multiple daily injections
AND 2) The patient is self-testing glucose levels 4 or more times per day OR the
patient is using a continuous glucose monitor AND 3) The patient has experienced any
of the following with the current diabetes regimen: inadequate glycemic control,
recurrent hypoglycemia, wide fluctuations in blood glucose, dawn phenomenon with
persistent severe early morning hyperglycemia, severe glycemic excursions.
-
-
Plan Year
For continuation of therapy with an insulin pump, the patient has stable or improved
glycemic control.
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 125
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 126
Prior Authorization Group VALCHLOR
Drug Names VALCHLOR
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Chronic or smoldering adult T-cell leukemia/lymphoma, Stage 2 or higher mycosis
fungoides/Sezary syndrome, primary cutaneous marginal zone lymphoma, primary
cutaneous follicle center lymphoma, lymphomatoid papulosis.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group VELCADE
Drug Names BORTEZOMIB, VELCADE
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Systemic light chain amyloidosis, Waldenstrom's
macroglobulinemia/lymphoplasmacytic lymphoma, multicentric Castleman's disease,
adult T-cell leukemia/lymphoma, acute lymphoblastic leukemia, AIDS-related Kaposi's
sarcoma, Hodgkin lymphoma, POEMS syndrome
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
Prior Authorization Group VELTASSA
Drug Names VELTASSA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The patient has experienced an inadequate treatment response, intolerance, or has a
contraindication to Lokelma.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 127
Prior Authorization Group VEMLIDY
Drug Names VEMLIDY
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria For chronic hepatitis B virus infection, the requested drug will be used in a patient who
meets either of the following (new starts only): 1) inadequate virologic response or
intolerable adverse event to tenofovir disoproxil fumarate OR 2) bone loss and
mineralization defects or is at risk for bone loss and mineralization defects (for
example, history of fragility fractures, advanced age, frailty, chronic glucocorticoid use,
low T-scores, or increased fall risk).
Prior Authorization Group VENCLEXTA
Drug Names VENCLEXTA, VENCLEXTA STARTING PACK
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Mantle cell lymphoma, blastic plasmacytoid dendritic cell neoplasm (BPDCN), multiple
myeloma, relapsed or refractory acute myeloid leukemia (AML), AML in patients 60
physiologic years of age or older.
Exclusion Criteria -
Required Medical Information For acute myeloid leukemia (AML), any of the following criteria must be met: 1) the
patient's physiologic age is 60 years of age or older OR 2) the requested drug will be
used as a component of repeating the initial successful induction regimen if late relapse
OR 3) the patient has comorbidities that preclude use of intensive induction
chemotherapy OR 4) the requested drug will be used for relapsed or refractory disease.
For blastic plasmacytoid dendritic cell neoplasm (BPDCN), any of the following criteria
must be met: 1) patient has systemic disease treated with palliative intent OR 2) patient
has relapsed or refractory disease. For multiple myeloma, all of the following must be
met: 1) the disease is relapsed or progressive AND 2) the requested drug will be used
in combination with dexamethasone AND 3) patient has t(11:14) translocation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 128
Prior Authorization Group VENTAVIS
Drug Names VENTAVIS
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For pulmonary arterial hypertension (World Health Organization [WHO] Group 1), the
diagnosis was confirmed by right heart catheterization. For new starts only: 1)
pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, 2)
pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg,
AND 3) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood
units.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
Prior Authorization Group VERSACLOZ
Drug Names VERSACLOZ
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For the treatment of a severely ill patient with schizophrenia who failed to respond
adequately to standard antipsychotic treatment (i.e., treatment-resistant schizophrenia),
1) the patient experienced an inadequate treatment response, intolerance, or
contraindication to one of the following generic products: A) aripiprazole, B) asenapine,
C) olanzapine, D) quetiapine, E) risperidone, F) ziprasidone AND 2) The patient
experienced an inadequate treatment response, intolerance, or contraindication to one
of the following brand products: A) Latuda, B) Rexulti, C) Secuado.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 129
Prior Authorization Group VERZENIO
Drug Names VERZENIO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent hormone receptor (HR)-positive, human epidermal growth factor receptor 2
(HER2)-negative breast cancer in combination with fulvestrant or an aromatase
inhibitor, or as a single agent if progression on prior endocrine therapy and prior
chemotherapy in the metastatic setting.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group VIGABATRIN
Drug Names VIGABATRIN, VIGADRONE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For complex partial seizures (CPS): patient had an inadequate response to at least 2
antiepileptic drugs for CPS.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group VITRAKVI
Drug Names VITRAKVI
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Advanced, recurrent, or persistent neurotrophic tyrosine receptor kinase (NTRK) gene
fusion-positive solid tumors, first-line treatment of NTRK gene fusion-positive solid
tumors.
Exclusion Criteria -
Required Medical Information For all neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors,
the disease is without a known acquired resistance mutation.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 130
Prior Authorization Group VIZIMPRO
Drug Names VIZIMPRO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent or advanced non-small cell lung cancer (NSCLC).
Exclusion Criteria -
Required Medical Information For non-small cell lung cancer (NSCLC): 1) the disease is recurrent, advanced or
metastatic, and 2) the patient has sensitizing EGFR mutation-positive disease.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group VORICONAZOLE
Drug Names VORICONAZOLE
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The patient will use the requested drug orally or intravenously.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 6 months
Other Criteria -
Prior Authorization Group VOSEVI
Drug Names VOSEVI
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria Decompensated cirrhosis/moderate or severe hepatic impairment (Child Turcotte Pugh
class B or C)
Required Medical Information For hepatitis C: Infection confirmed by presence of HCV RNA in the serum prior to
starting treatment. Planned treatment regimen, genotype, prior treatment history,
presence or absence of cirrhosis (compensated or decompensated [Child Turcotte
Pugh class B or C]), presence or absence of HIV coinfection, presence or absence of
resistance-associated substitutions where applicable, liver and kidney transplantation
status if applicable. Coverage conditions and specific durations of approval will be
based on current AASLD treatment guidelines.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Criteria will be applied consistent with current AASLD-IDSA guidance.
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 131
Prior Authorization Group VOTRIENT
Drug Names VOTRIENT
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Thyroid carcinoma (follicular, papillary, Hurthle cell, or medullary), uterine sarcoma.
Exclusion Criteria -
Required Medical Information For renal cell carcinoma: The disease is advanced, relapsed, or stage IV. For soft
tissue sarcoma (STS): The patient does not have an adipocytic soft tissue sarcoma.
For uterine sarcoma: The disease is recurrent or metastatic.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group VRAYLAR
Drug Names VRAYLAR
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For treatment of schizophrenia: 1) The patient experienced an inadequate treatment
response, intolerance, or contraindication to one of the following generic products:
aripiprazole, asenapine, olanzapine, quetiapine, risperidone, ziprasidone AND 2) The
patient experienced an inadequate treatment response, intolerance, or contraindication
to one of the following brand products: Latuda, Rexulti, Secuado. For acute treatment
of manic or mixed episodes associated with bipolar I disorder: The patient experienced
an inadequate treatment response, intolerance, or contraindication to one of the
following generic products: aripiprazole, asenapine, olanzapine, quetiapine,
risperidone, ziprasidone. For treatment of depressive episodes associated with bipolar I
disorder (bipolar depression): 1)The patient experienced an inadequate treatment
response, intolerance, or contraindication to one of the following generic products:
olanzapine, quetiapine, AND 2) The patient experienced an inadequate treatment
response, intolerance, or contraindication to brand Latuda.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 132
Prior Authorization Group XALKORI
Drug Names XALKORI
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent non-small cell lung cancer (NSCLC), NSCLC with high-level MET
amplification or MET exon 14 skipping mutation, inflammatory myofibroblastic tumors
(IMT).
Exclusion Criteria -
Required Medical Information For NSCLC, the requested drug is used in any of the following settings: 1) the patient
has recurrent, advanced or metastatic ALK-positive NSCLC, 2) the patient has
recurrent, advanced or metastatic ROS-1 positive NSCLC, or 3) the patient has NSCLC
with high-level MET amplification or MET exon 14 skipping mutation. For IMT, the
disease is ALK-positive. For anaplastic large cell lymphoma, the disease is relapsed or
refractory and ALK-positive.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group XELJANZ
Drug Names XELJANZ, XELJANZ XR
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For moderately to severely active rheumatoid arthritis (new starts only): 1) Inadequate
response, intolerance or contraindication to methotrexate (MTX), OR 2) Inadequate
response or intolerance to a prior biologic disease-modifying antirheumatic drug
(DMARD) or a targeted synthetic DMARD. For active psoriatic arthritis (new starts
only): The requested drug is used in combination with a nonbiologic DMARD. For
moderately to severely active ulcerative colitis (new starts only): Inadequate response,
intolerance or contraindication to a tumor necrosis factor (TNF) blocker.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 133
Prior Authorization Group XERMELO
Drug Names XERMELO
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group XGEVA
Drug Names XGEVA
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For hypercalcemia of malignancy: condition is refractory to intravenous (IV)
bisphosphonate therapy or there is a clinical reason to avoid IV bisphosphonate
therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
Prior Authorization Group XIFAXAN
Drug Names XIFAXAN
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The requested drug is being prescribed to reduce the risk of overt hepatic
encephalopathy (HE) recurrence OR 2) The patient has the diagnosis of irritable bowel
syndrome with diarrhea (IBS-D) AND 3) If the patient has previously received treatment
with the requested drug, the patient has experienced a recurrence of symptoms AND 4)
The patient has not already received an initial 14-day course of treatment and two
additional 14-day courses of treatment with the requested drug OR 5) The patient has
not previously received treatment with the requested drug.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Reduction in risk of overt HE recurrence: 6 months, IBS-D: 14 days
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 134
Prior Authorization Group XOLAIR
Drug Names XOLAIR
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information For allergic asthma initial therapy: 1) Patient has positive skin test (or blood test) to at
least 1 perennial aeroallergen, 2) Patient has baseline IgE level greater than or equal to
30 IU/mL, and 3) Patient has inadequate asthma control despite current treatment with
both of the following medications at optimized doses: a) Inhaled corticosteroid, and b)
Additional controller (long acting beta2-agonist, leukotriene modifier, or sustained-
release theophylline) unless patient has an intolerance or contraindication to such
therapies. For allergic asthma continuation therapy only: Patient's asthma control has
improved on treatment with the requested drug since initiation of therapy. For chronic
idiopathic urticaria (CIU) initial therapy: 1) Patient has been evaluated for other causes
of urticaria, including bradykinin-related angioedema and IL-1-associated urticarial
syndromes (auto-inflammatory disorders, urticarial vasculitis), and 2) Patient has
experienced a spontaneous onset of wheals, angioedema, or both, for at least 6 weeks.
For CIU continuation therapy: Patient has experienced a response (e.g., improved
symptoms) since initiation of therapy.
Age Restrictions For CIU: 12 years of age or older. For allergic asthma: 6 years of age or older. For
nasal polyps: 18 years of age or older.
Prescriber Restrictions -
Coverage Duration Allergic asthma and nasal polyps: Plan Year. CIU initial: 6 months. CIU continuation:
Plan Year
Other Criteria -
Prior Authorization Group XOSPATA
Drug Names XOSPATA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and FLT3
rearrangement
Exclusion Criteria -
Required Medical Information For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and FLT3
rearrangement: the disease is in chronic or blast phase.
Age Restrictions 18 years of age or older
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 135
Prior Authorization Group XPOVIO
Drug Names XPOVIO, XPOVIO 100 MG ONCE WEEKLY, XPOVIO 40 MG ONCE WEEKLY,
XPOVIO 40 MG TWICE WEEKLY, XPOVIO 60 MG ONCE WEEKLY, XPOVIO 60 MG
TWICE WEEKLY, XPOVIO 80 MG ONCE WEEKLY, XPOVIO 80 MG TWICE WEEKLY
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group XTANDI
Drug Names XTANDI
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information The requested drug will be used in combination with a gonadotropin-releasing hormone
(GnRH) analog or after bilateral orchiectomy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 136
Prior Authorization Group XYREM
Drug Names XYREM
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information 1) The requested drug is being prescribed for the treatment of excessive daytime
sleepiness in a patient 7 years of age or older with narcolepsy AND 2) The diagnosis
has been confirmed by sleep lab evaluation AND 3)The patient experienced an
inadequate treatment response or intolerance to at least one central nervous system
(CNS) stimulant drug (e.g., amphetamine, dextroamphetamine, or methylphenidate)
OR has a contraindication that would prohibit a trial of central nervous system (CNS)
stimulant drugs (e.g., amphetamine, dextroamphetamine, or methylphenidate) [Note:
Coverage of amphetamines may require prior authorization.] AND 4) If the patient is 18
years of age or older, the patient experienced an inadequate treatment response or
intolerance to at least one central nervous system (CNS) wakefulness promoting drug
(e.g., armodafinil) OR has a contraindication that would prohibit a trial of central
nervous system (CNS) wakefulness promoting drugs (e.g., armodafinil) [Note: coverage
of armodafinil may require prior authorization.] OR 5) The requested drug is being
prescribed for the treatment of cataplexy in a patient 7 years of age or older with
narcolepsy AND 6) The diagnosis has been confirmed by sleep lab evaluation.
Age Restrictions 7 years of age or older
Prescriber Restrictions Prescribed by or in consultation with a sleep disorder specialist or neurologist.
Coverage Duration Plan Year
Other Criteria If the request is for a continuation of therapy, then the patient experienced a decrease
in daytime sleepiness with narcolepsy or a decrease in cataplexy episodes with
narcolepsy.
Prior Authorization Group ZARXIO
Drug Names ZARXIO
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Neutropenia in myelodysplastic syndromes (MDS), agranulocytosis, neutropenia in
aplastic anemia, human immunodeficiency virus (HIV)-related neutropenia, neutropenia
related to renal transplant.
Exclusion Criteria Use of the requested product within 24 hours prior to or following chemotherapy.
Required Medical Information For prophylaxis or treatment of myelosuppressive chemotherapy-induced febrile
neutropenia (FN) patient must meet both of the following: 1) Patient has a solid tumor
or non-myeloid cancer, and 2) Patient has received, is currently receiving, or will be
receiving treatment with myelosuppressive anti-cancer therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration 6 months
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 137
Prior Authorization Group ZEJULA
Drug Names ZEJULA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses In combination with bevacizumab for persistent or recurrent epithelial ovarian, fallopian
tube, or primary peritoneal cancer for platinum-sensitive disease.
Exclusion Criteria -
Required Medical Information For ovarian, fallopian tube, or primary peritoneal cancer, the requested drug is used in
any of the following settings: 1) as maintenance treatment of stage II-IV epithelial
ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete
or partial response to first-line platinum-based chemotherapy AND if it is known that the
patient has breast cancer susceptibility gene (BRCA)-mutated disease, the patient
experienced an unacceptable toxicity with a trial of Lynparza (olaparib), 2) as
maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary
peritoneal cancer in patients who are in a complete or partial response to
chemotherapy AND the patient experienced an unacceptable toxicity with a trial of
Lynparza (olaparib), 3) as treatment of advanced, persistent, or recurrent ovarian,
fallopian tube, or primary peritoneal cancer in patients treated with three or more prior
chemotherapy regimens and whose cancer is associated with homologous
recombination deficiency (HRD) positive status defined by either a) a deleterious or
suspected deleterious BRCA mutation AND if prescribed for advanced, persistent, or
recurrent ovarian cancer with deleterious or suspected deleterious germline BRCA
mutation, the patient experienced an unacceptable toxicity with a trial of Lynparza
(olaparib), or b) genomic instability and progression more than six months after
response to the last platinum-based chemotherapy, or 4) in combination with
bevacizumab for platinum-sensitive persistent or recurrent epithelial ovarian, fallopian
tube, or primary peritoneal cancer.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 138
Prior Authorization Group ZELBORAF
Drug Names ZELBORAF
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Non-small cell lung cancer, hairy cell leukemia, thyroid carcinoma (i.e., papillary
carcinoma, follicular carcinoma, and Hurthle cell carcinoma), central nervous system
cancer (i.e., glioma, meningioma, astrocytoma), adjuvant systemic therapy for
cutaneous melanoma.
Exclusion Criteria -
Required Medical Information For adjuvant treatment of melanoma, and central nervous system (CNS) cancer (i.e.,
glioma, meningioma, astrocytoma): 1) The tumor is positive for BRAF V600 activating
mutation (e.g., V600E or V600K) and 2) The requested drug will be used in
combination with cobimetinib. For unresectable or metastatic melanoma: 1) The tumor
is positive for BRAF V600 activating mutation (e.g., V600E or V600K) and 2) the
requested drug will be used as a single agent, or in combination with cobimetinib (with
or without atezolizumab). For Erdheim-Chester Disease: Tumor is positive for BRAF
V600 mutation. For non-small cell lung cancer: 1) Tumor is positive for the BRAF
V600E mutation, and 2) The patient has recurrent, advanced, or metastatic disease.
For thyroid carcinoma: 1) Tumor is positive for BRAF mutation, and 2) Patient has
radioiodine refractory follicular, Hurthle cell, or papillary thyroid carcinoma. For hairy
cell leukemia: The requested drug will be used for subsequent therapy.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 139
Prior Authorization Group ZIRABEV
Drug Names ZIRABEV
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Breast cancer, central nervous system (CNS) tumor types: adult low-grade (WHO
Grade II) infiltrative supratentorial astrocytoma/oligodendroglioma, adult intracranial
and spinal ependymoma, anaplastic gliomas, adult medulloblastoma, primary central
nervous system lymphoma, meningiomas, limited and extensive brain metastases,
metastatic spine tumors, malignant pleural mesothelioma, epithelial ovarian
cancer/fallopian tube cancer/primary peritoneal cancer, including the following cancer
types: carcinosarcoma (malignant mixed Mullerian tumors), clear cell carcinoma,
mucinous carcinoma, grade 1 endometrioid carcinoma, low-grade serous carcinoma,
ovarian borderline epithelial tumors (low malignant potential) with invasive implants,
and malignant sex cord-stromal tumors, soft tissue sarcoma types: angiosarcoma and
solitary fibrous tumor/hemangiopericytoma, uterine neoplasms, endometrial carcinoma,
vulvar squamous cell carcinoma, and ophthalmic-related disorders: diabetic macular
edema, neovascular (wet) age-related macular degeneration including polypoidal
choroidopathy and retinal angiomatous proliferation subtypes, macular edema following
retinal vein occlusion, proliferative diabetic retinopathy, choroidal neovascularization,
neovascular glaucoma and retinopathy of prematurity, hepatocellular carcinoma, small
bowel adenocarcinoma.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria Coverage under Part D will be denied if coverage is available under Part A or Part B as
the medication is prescribed and dispensed or administered for the individual.
Prior Authorization Group ZOLINZA
Drug Names ZOLINZA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Mycosis fungoides, Sezary syndrome.
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 140
Prior Authorization Group ZYDELIG
Drug Names ZYDELIG
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic
lymphoma (SLL), relapsed or refractory follicular lymphoma, and marginal zone
lymphomas [nodal marginal zone lymphoma, gastric mucosa associated lymphoid
tissue (MALT) lymphoma, non-gastric MALT lymphoma, and splenic marginal zone
lymphoma].
Exclusion Criteria -
Required Medical Information -
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ZYKADIA
Drug Names ZYKADIA
PA Indication Indicator All FDA-approved Indications, Some Medically-accepted Indications
Off-label Uses Recurrent or advanced ALK-positive non-small cell lung cancer (NSCLC), recurrent,
advanced, or metastatic ROS1-positive NSCLC, inflammatory myofibroblastic tumor
(IMT), brain metastases from NSCLC.
Exclusion Criteria -
Required Medical Information For NSCLC: the patient has recurrent, advanced, or metastatic ALK-positive or ROS1-
positive disease. For inflammatory myofibroblastic tumor: the disease is ALK-positive.
For brain metastases from NSCLC: the patient has ALK-positive NSCLC.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
Prior Authorization Group ZYPREXA RELPREVV
Drug Names ZYPREXA RELPREVV
PA Indication Indicator All FDA-approved Indications
Off-label Uses -
Exclusion Criteria -
Required Medical Information Tolerability with oral olanzapine has been established.
Age Restrictions -
Prescriber Restrictions -
Coverage Duration Plan Year
Other Criteria -
H5280_NSR_19_476_OHMMPPAGrid
Updated 01/01/2022 141
Molina Dual Options MyCare Ohio Medicare-Medicaid Plan is a health plan that contracts with both Medicare
and Ohio Medicaid to provide benefits of both programs to enrollees.
You can get this document for free in other formats, such as large print, braille, or audio. Call (855) 665-4623,
TTY: 711, Monday - Friday, 8 a.m. to 8 p.m., local time. The call is free.